{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Chemical-Disease Relation (CDR) Tutorial\n",
    "\n",
    "In this example, we'll be writing an application to extract *mentions of* **chemical-induced-disease relationships** from Pubmed abstracts, as per the [BioCreative CDR Challenge](http://www.biocreative.org/resources/corpora/biocreative-v-cdr-corpus/).  This tutorial will show off some of the more advanced features of Snorkel, so we'll assume you've followed the Intro tutorial."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Let's start by reloading from the last notebook."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "%load_ext autoreload\n",
    "%autoreload 2\n",
    "%matplotlib inline\n",
    "\n",
    "from snorkel import SnorkelSession\n",
    "\n",
    "session = SnorkelSession()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "from snorkel.models import candidate_subclass\n",
    "\n",
    "ChemicalDisease = candidate_subclass('ChemicalDisease', ['chemical', 'disease'])\n",
    "\n",
    "train_cands = session.query(ChemicalDisease).filter(ChemicalDisease.split == 0).all()\n",
    "dev_cands = session.query(ChemicalDisease).filter(ChemicalDisease.split == 1).all()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Part III: Writing LFs\n",
    "\n",
    "This tutorial features some more advanced LFs than the intro tutorial, with more focus on distant supervision and dependencies between LFs."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Distant supervision approaches"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "We'll use the [Comparative Toxicogenomics Database](http://ctdbase.org/) (CTD) for distant supervision. The CTD lists chemical-condition entity pairs under three categories: therapy, marker, and unspecified. Therapy means the chemical treats the condition, marker means the chemical is typically present with the condition, and unspecified is...unspecified. We can write LFs based on these categories."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "import bz2\n",
    "from six.moves.cPickle import load\n",
    "\n",
    "with bz2.BZ2File('data/ctd.pkl.bz2', 'rb') as ctd_f:\n",
    "    ctd_unspecified, ctd_therapy, ctd_marker = load(ctd_f)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "def cand_in_ctd_unspecified(c):\n",
    "    return 1 if c.get_cids() in ctd_unspecified else 0\n",
    "\n",
    "def cand_in_ctd_therapy(c):\n",
    "    return 1 if c.get_cids() in ctd_therapy else 0\n",
    "\n",
    "def cand_in_ctd_marker(c):\n",
    "    return 1 if c.get_cids() in ctd_marker else 0"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "def LF_in_ctd_unspecified(c):\n",
    "    return -1 * cand_in_ctd_unspecified(c)\n",
    "\n",
    "def LF_in_ctd_therapy(c):\n",
    "    return -1 * cand_in_ctd_therapy(c)\n",
    "\n",
    "def LF_in_ctd_marker(c):\n",
    "    return cand_in_ctd_marker(c)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Text pattern approaches\n",
    "\n",
    "Now we'll use some LF helpers to create LFs based on indicative text patterns. We came up with these rules by using the viewer to examine training candidates and noting frequent patterns."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "import re\n",
    "from snorkel.lf_helpers import (\n",
    "    get_tagged_text,\n",
    "    rule_regex_search_tagged_text,\n",
    "    rule_regex_search_btw_AB,\n",
    "    rule_regex_search_btw_BA,\n",
    "    rule_regex_search_before_A,\n",
    "    rule_regex_search_before_B,\n",
    ")\n",
    "\n",
    "# List to parenthetical\n",
    "def ltp(x):\n",
    "    return '(' + '|'.join(x) + ')'\n",
    "\n",
    "def LF_induce(c):\n",
    "    return 1 if re.search(r'{{A}}.{0,20}induc.{0,20}{{B}}', get_tagged_text(c), flags=re.I) else 0\n",
    "\n",
    "causal_past = ['induced', 'caused', 'due']\n",
    "def LF_d_induced_by_c(c):\n",
    "    return rule_regex_search_btw_BA(c, '.{0,50}' + ltp(causal_past) + '.{0,9}(by|to).{0,50}', 1)\n",
    "def LF_d_induced_by_c_tight(c):\n",
    "    return rule_regex_search_btw_BA(c, '.{0,50}' + ltp(causal_past) + ' (by|to) ', 1)\n",
    "\n",
    "def LF_induce_name(c):\n",
    "    return 1 if 'induc' in c.chemical.get_span().lower() else 0     \n",
    "\n",
    "causal = ['cause[sd]?', 'induce[sd]?', 'associated with']\n",
    "def LF_c_cause_d(c):\n",
    "    return 1 if (\n",
    "        re.search(r'{{A}}.{0,50} ' + ltp(causal) + '.{0,50}{{B}}', get_tagged_text(c), re.I)\n",
    "        and not re.search('{{A}}.{0,50}(not|no).{0,20}' + ltp(causal) + '.{0,50}{{B}}', get_tagged_text(c), re.I)\n",
    "    ) else 0\n",
    "\n",
    "treat = ['treat', 'effective', 'prevent', 'resistant', 'slow', 'promise', 'therap']\n",
    "def LF_d_treat_c(c):\n",
    "    return rule_regex_search_btw_BA(c, '.{0,50}' + ltp(treat) + '.{0,50}', -1)\n",
    "def LF_c_treat_d(c):\n",
    "    return rule_regex_search_btw_AB(c, '.{0,50}' + ltp(treat) + '.{0,50}', -1)\n",
    "def LF_treat_d(c):\n",
    "    return rule_regex_search_before_B(c, ltp(treat) + '.{0,50}', -1)\n",
    "def LF_c_treat_d_wide(c):\n",
    "    return rule_regex_search_btw_AB(c, '.{0,200}' + ltp(treat) + '.{0,200}', -1)\n",
    "\n",
    "def LF_c_d(c):\n",
    "    return 1 if ('{{A}} {{B}}' in get_tagged_text(c)) else 0\n",
    "\n",
    "def LF_c_induced_d(c):\n",
    "    return 1 if (\n",
    "        ('{{A}} {{B}}' in get_tagged_text(c)) and \n",
    "        (('-induc' in c[0].get_span().lower()) or ('-assoc' in c[0].get_span().lower()))\n",
    "        ) else 0\n",
    "\n",
    "def LF_improve_before_disease(c):\n",
    "    return rule_regex_search_before_B(c, 'improv.*', -1)\n",
    "\n",
    "pat_terms = ['in a patient with ', 'in patients with']\n",
    "def LF_in_patient_with(c):\n",
    "    return -1 if re.search(ltp(pat_terms) + '{{B}}', get_tagged_text(c), flags=re.I) else 0\n",
    "\n",
    "uncertain = ['combin', 'possible', 'unlikely']\n",
    "def LF_uncertain(c):\n",
    "    return rule_regex_search_before_A(c, ltp(uncertain) + '.*', -1)\n",
    "\n",
    "def LF_induced_other(c):\n",
    "    return rule_regex_search_tagged_text(c, '{{A}}.{20,1000}-induced {{B}}', -1)\n",
    "\n",
    "def LF_far_c_d(c):\n",
    "    return rule_regex_search_btw_AB(c, '.{100,5000}', -1)\n",
    "\n",
    "def LF_far_d_c(c):\n",
    "    return rule_regex_search_btw_BA(c, '.{100,5000}', -1)\n",
    "\n",
    "def LF_risk_d(c):\n",
    "    return rule_regex_search_before_B(c, 'risk of ', 1)\n",
    "\n",
    "def LF_develop_d_following_c(c):\n",
    "    return 1 if re.search(r'develop.{0,25}{{B}}.{0,25}following.{0,25}{{A}}', get_tagged_text(c), flags=re.I) else 0\n",
    "\n",
    "procedure, following = ['inject', 'administrat'], ['following']\n",
    "def LF_d_following_c(c):\n",
    "    return 1 if re.search('{{B}}.{0,50}' + ltp(following) + '.{0,20}{{A}}.{0,50}' + ltp(procedure), get_tagged_text(c), flags=re.I) else 0\n",
    "\n",
    "def LF_measure(c):\n",
    "    return -1 if re.search('measur.{0,75}{{A}}', get_tagged_text(c), flags=re.I) else 0\n",
    "\n",
    "def LF_level(c):\n",
    "    return -1 if re.search('{{A}}.{0,25} level', get_tagged_text(c), flags=re.I) else 0\n",
    "\n",
    "def LF_neg_d(c):\n",
    "    return -1 if re.search('(none|not|no) .{0,25}{{B}}', get_tagged_text(c), flags=re.I) else 0\n",
    "\n",
    "WEAK_PHRASES = ['none', 'although', 'was carried out', 'was conducted',\n",
    "                'seems', 'suggests', 'risk', 'implicated',\n",
    "               'the aim', 'to (investigate|assess|study)']\n",
    "\n",
    "WEAK_RGX = r'|'.join(WEAK_PHRASES)\n",
    "\n",
    "def LF_weak_assertions(c):\n",
    "    return -1 if re.search(WEAK_RGX, get_tagged_text(c), flags=re.I) else 0"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Composite LFs\n",
    "\n",
    "The following LFs take some of the strongest distant supervision and text pattern LFs, and combine them to form more specific LFs. These LFs introduce some obvious dependencies within the LF set, which we will model later."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "def LF_ctd_marker_c_d(c):\n",
    "    return LF_c_d(c) * cand_in_ctd_marker(c)\n",
    "\n",
    "def LF_ctd_marker_induce(c):\n",
    "    return (LF_c_induced_d(c) or LF_d_induced_by_c_tight(c)) * cand_in_ctd_marker(c)\n",
    "\n",
    "def LF_ctd_therapy_treat(c):\n",
    "    return LF_c_treat_d_wide(c) * cand_in_ctd_therapy(c)\n",
    "\n",
    "def LF_ctd_unspecified_treat(c):\n",
    "    return LF_c_treat_d_wide(c) * cand_in_ctd_unspecified(c)\n",
    "\n",
    "def LF_ctd_unspecified_induce(c):\n",
    "    return (LF_c_induced_d(c) or LF_d_induced_by_c_tight(c)) * cand_in_ctd_unspecified(c)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Rules based on context hierarchy\n",
    "\n",
    "These last two rules will make use of the context hierarchy. The first checks if there is a chemical mention much closer to the candidate's disease mention than the candidate's chemical mention. The second does the analog for diseases."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "def LF_closer_chem(c):\n",
    "    # Get distance between chemical and disease\n",
    "    chem_start, chem_end = c.chemical.get_word_start(), c.chemical.get_word_end()\n",
    "    dis_start, dis_end = c.disease.get_word_start(), c.disease.get_word_end()\n",
    "    if dis_start < chem_start:\n",
    "        dist = chem_start - dis_end\n",
    "    else:\n",
    "        dist = dis_start - chem_end\n",
    "    # Try to find chemical closer than @dist/2 in either direction\n",
    "    sent = c.get_parent()\n",
    "    closest_other_chem = float('inf')\n",
    "    for i in range(dis_end, min(len(sent.words), dis_end + dist // 2)):\n",
    "        et, cid = sent.entity_types[i], sent.entity_cids[i]\n",
    "        if et == 'Chemical' and cid != sent.entity_cids[chem_start]:\n",
    "            return -1\n",
    "    for i in range(max(0, dis_start - dist // 2), dis_start):\n",
    "        et, cid = sent.entity_types[i], sent.entity_cids[i]\n",
    "        if et == 'Chemical' and cid != sent.entity_cids[chem_start]:\n",
    "            return -1\n",
    "    return 0\n",
    "\n",
    "def LF_closer_dis(c):\n",
    "    # Get distance between chemical and disease\n",
    "    chem_start, chem_end = c.chemical.get_word_start(), c.chemical.get_word_end()\n",
    "    dis_start, dis_end = c.disease.get_word_start(), c.disease.get_word_end()\n",
    "    if dis_start < chem_start:\n",
    "        dist = chem_start - dis_end\n",
    "    else:\n",
    "        dist = dis_start - chem_end\n",
    "    # Try to find chemical disease than @dist/8 in either direction\n",
    "    sent = c.get_parent()\n",
    "    for i in range(chem_end, min(len(sent.words), chem_end + dist // 8)):\n",
    "        et, cid = sent.entity_types[i], sent.entity_cids[i]\n",
    "        if et == 'Disease' and cid != sent.entity_cids[dis_start]:\n",
    "            return -1\n",
    "    for i in range(max(0, chem_start - dist // 8), chem_start):\n",
    "        et, cid = sent.entity_types[i], sent.entity_cids[i]\n",
    "        if et == 'Disease' and cid != sent.entity_cids[dis_start]:\n",
    "            return -1\n",
    "    return 0"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Running the LFs on the training set"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "LFs = [\n",
    "    LF_c_cause_d,\n",
    "    LF_c_d,\n",
    "    LF_c_induced_d,\n",
    "    LF_c_treat_d,\n",
    "    LF_c_treat_d_wide,\n",
    "    LF_closer_chem,\n",
    "    LF_closer_dis,\n",
    "    LF_ctd_marker_c_d,\n",
    "    LF_ctd_marker_induce,\n",
    "    LF_ctd_therapy_treat,\n",
    "    LF_ctd_unspecified_treat,\n",
    "    LF_ctd_unspecified_induce,\n",
    "    LF_d_following_c,\n",
    "    LF_d_induced_by_c,\n",
    "    LF_d_induced_by_c_tight,\n",
    "    LF_d_treat_c,\n",
    "    LF_develop_d_following_c,\n",
    "    LF_far_c_d,\n",
    "    LF_far_d_c,\n",
    "    LF_improve_before_disease,\n",
    "    LF_in_ctd_therapy,\n",
    "    LF_in_ctd_marker,\n",
    "    LF_in_patient_with,\n",
    "    LF_induce,\n",
    "    LF_induce_name,\n",
    "    LF_induced_other,\n",
    "    LF_level,\n",
    "    LF_measure,\n",
    "    LF_neg_d,\n",
    "    LF_risk_d,\n",
    "    LF_treat_d,\n",
    "    LF_uncertain,\n",
    "    LF_weak_assertions,\n",
    "]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "from snorkel.annotations import LabelAnnotator\n",
    "labeler = LabelAnnotator(lfs=LFs)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Clearing existing...\n",
      "Running UDF...\n",
      "[========================================] 100%\n",
      "\n",
      "CPU times: user 45 s, sys: 328 ms, total: 45.3 s\n",
      "Wall time: 45.7 s\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "<8432x33 sparse matrix of type '<class 'numpy.int64'>'\n",
       "\twith 17438 stored elements in Compressed Sparse Row format>"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "%time L_train = labeler.apply(split=0)\n",
    "L_train"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<sqlalchemy.orm.session.Session at 0x114c91cf8>"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "session"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>j</th>\n",
       "      <th>Coverage</th>\n",
       "      <th>Overlaps</th>\n",
       "      <th>Conflicts</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>LF_c_cause_d</th>\n",
       "      <td>0</td>\n",
       "      <td>0.031665</td>\n",
       "      <td>0.027989</td>\n",
       "      <td>0.012690</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_c_d</th>\n",
       "      <td>1</td>\n",
       "      <td>0.021703</td>\n",
       "      <td>0.018145</td>\n",
       "      <td>0.005693</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_c_induced_d</th>\n",
       "      <td>2</td>\n",
       "      <td>0.004151</td>\n",
       "      <td>0.004151</td>\n",
       "      <td>0.001898</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_c_treat_d</th>\n",
       "      <td>3</td>\n",
       "      <td>0.047676</td>\n",
       "      <td>0.047676</td>\n",
       "      <td>0.019924</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_c_treat_d_wide</th>\n",
       "      <td>4</td>\n",
       "      <td>0.088591</td>\n",
       "      <td>0.087524</td>\n",
       "      <td>0.037832</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_closer_chem</th>\n",
       "      <td>5</td>\n",
       "      <td>0.188449</td>\n",
       "      <td>0.169592</td>\n",
       "      <td>0.091556</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_closer_dis</th>\n",
       "      <td>6</td>\n",
       "      <td>0.014587</td>\n",
       "      <td>0.014113</td>\n",
       "      <td>0.009013</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_ctd_marker_c_d</th>\n",
       "      <td>7</td>\n",
       "      <td>0.017671</td>\n",
       "      <td>0.017671</td>\n",
       "      <td>0.005337</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_ctd_marker_induce</th>\n",
       "      <td>8</td>\n",
       "      <td>0.020398</td>\n",
       "      <td>0.020398</td>\n",
       "      <td>0.008065</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_ctd_therapy_treat</th>\n",
       "      <td>9</td>\n",
       "      <td>0.047201</td>\n",
       "      <td>0.047201</td>\n",
       "      <td>0.017315</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_ctd_unspecified_treat</th>\n",
       "      <td>10</td>\n",
       "      <td>0.057993</td>\n",
       "      <td>0.057993</td>\n",
       "      <td>0.028582</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_ctd_unspecified_induce</th>\n",
       "      <td>11</td>\n",
       "      <td>0.016603</td>\n",
       "      <td>0.016603</td>\n",
       "      <td>0.007472</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_d_following_c</th>\n",
       "      <td>12</td>\n",
       "      <td>0.000474</td>\n",
       "      <td>0.000474</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_d_induced_by_c</th>\n",
       "      <td>13</td>\n",
       "      <td>0.036409</td>\n",
       "      <td>0.033681</td>\n",
       "      <td>0.015062</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_d_induced_by_c_tight</th>\n",
       "      <td>14</td>\n",
       "      <td>0.017552</td>\n",
       "      <td>0.017552</td>\n",
       "      <td>0.006286</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_d_treat_c</th>\n",
       "      <td>15</td>\n",
       "      <td>0.027277</td>\n",
       "      <td>0.023838</td>\n",
       "      <td>0.014824</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_develop_d_following_c</th>\n",
       "      <td>16</td>\n",
       "      <td>0.000830</td>\n",
       "      <td>0.000830</td>\n",
       "      <td>0.000474</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_far_c_d</th>\n",
       "      <td>17</td>\n",
       "      <td>0.109108</td>\n",
       "      <td>0.096893</td>\n",
       "      <td>0.053843</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_far_d_c</th>\n",
       "      <td>18</td>\n",
       "      <td>0.081831</td>\n",
       "      <td>0.070446</td>\n",
       "      <td>0.043525</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_improve_before_disease</th>\n",
       "      <td>19</td>\n",
       "      <td>0.001542</td>\n",
       "      <td>0.001423</td>\n",
       "      <td>0.000712</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_in_ctd_therapy</th>\n",
       "      <td>20</td>\n",
       "      <td>0.298506</td>\n",
       "      <td>0.257709</td>\n",
       "      <td>0.170422</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_in_ctd_marker</th>\n",
       "      <td>21</td>\n",
       "      <td>0.611954</td>\n",
       "      <td>0.442007</td>\n",
       "      <td>0.346893</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_in_patient_with</th>\n",
       "      <td>22</td>\n",
       "      <td>0.001542</td>\n",
       "      <td>0.000830</td>\n",
       "      <td>0.000474</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_induce</th>\n",
       "      <td>23</td>\n",
       "      <td>0.089658</td>\n",
       "      <td>0.084203</td>\n",
       "      <td>0.030123</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_induce_name</th>\n",
       "      <td>24</td>\n",
       "      <td>0.006523</td>\n",
       "      <td>0.006286</td>\n",
       "      <td>0.003439</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_induced_other</th>\n",
       "      <td>25</td>\n",
       "      <td>0.040916</td>\n",
       "      <td>0.040204</td>\n",
       "      <td>0.019094</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_level</th>\n",
       "      <td>26</td>\n",
       "      <td>0.006760</td>\n",
       "      <td>0.005100</td>\n",
       "      <td>0.002846</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_measure</th>\n",
       "      <td>27</td>\n",
       "      <td>0.003676</td>\n",
       "      <td>0.002846</td>\n",
       "      <td>0.002491</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_neg_d</th>\n",
       "      <td>28</td>\n",
       "      <td>0.018382</td>\n",
       "      <td>0.015299</td>\n",
       "      <td>0.011504</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_risk_d</th>\n",
       "      <td>29</td>\n",
       "      <td>0.005337</td>\n",
       "      <td>0.005337</td>\n",
       "      <td>0.005337</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_treat_d</th>\n",
       "      <td>30</td>\n",
       "      <td>0.022059</td>\n",
       "      <td>0.019687</td>\n",
       "      <td>0.011504</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_uncertain</th>\n",
       "      <td>31</td>\n",
       "      <td>0.018264</td>\n",
       "      <td>0.016841</td>\n",
       "      <td>0.007590</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_weak_assertions</th>\n",
       "      <td>32</td>\n",
       "      <td>0.112785</td>\n",
       "      <td>0.099146</td>\n",
       "      <td>0.069023</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                            j  Coverage  Overlaps  Conflicts\n",
       "LF_c_cause_d                0  0.031665  0.027989   0.012690\n",
       "LF_c_d                      1  0.021703  0.018145   0.005693\n",
       "LF_c_induced_d              2  0.004151  0.004151   0.001898\n",
       "LF_c_treat_d                3  0.047676  0.047676   0.019924\n",
       "LF_c_treat_d_wide           4  0.088591  0.087524   0.037832\n",
       "LF_closer_chem              5  0.188449  0.169592   0.091556\n",
       "LF_closer_dis               6  0.014587  0.014113   0.009013\n",
       "LF_ctd_marker_c_d           7  0.017671  0.017671   0.005337\n",
       "LF_ctd_marker_induce        8  0.020398  0.020398   0.008065\n",
       "LF_ctd_therapy_treat        9  0.047201  0.047201   0.017315\n",
       "LF_ctd_unspecified_treat   10  0.057993  0.057993   0.028582\n",
       "LF_ctd_unspecified_induce  11  0.016603  0.016603   0.007472\n",
       "LF_d_following_c           12  0.000474  0.000474   0.000000\n",
       "LF_d_induced_by_c          13  0.036409  0.033681   0.015062\n",
       "LF_d_induced_by_c_tight    14  0.017552  0.017552   0.006286\n",
       "LF_d_treat_c               15  0.027277  0.023838   0.014824\n",
       "LF_develop_d_following_c   16  0.000830  0.000830   0.000474\n",
       "LF_far_c_d                 17  0.109108  0.096893   0.053843\n",
       "LF_far_d_c                 18  0.081831  0.070446   0.043525\n",
       "LF_improve_before_disease  19  0.001542  0.001423   0.000712\n",
       "LF_in_ctd_therapy          20  0.298506  0.257709   0.170422\n",
       "LF_in_ctd_marker           21  0.611954  0.442007   0.346893\n",
       "LF_in_patient_with         22  0.001542  0.000830   0.000474\n",
       "LF_induce                  23  0.089658  0.084203   0.030123\n",
       "LF_induce_name             24  0.006523  0.006286   0.003439\n",
       "LF_induced_other           25  0.040916  0.040204   0.019094\n",
       "LF_level                   26  0.006760  0.005100   0.002846\n",
       "LF_measure                 27  0.003676  0.002846   0.002491\n",
       "LF_neg_d                   28  0.018382  0.015299   0.011504\n",
       "LF_risk_d                  29  0.005337  0.005337   0.005337\n",
       "LF_treat_d                 30  0.022059  0.019687   0.011504\n",
       "LF_uncertain               31  0.018264  0.016841   0.007590\n",
       "LF_weak_assertions         32  0.112785  0.099146   0.069023"
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "L_train.lf_stats(session)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Part IV: Training the generative model\n",
    "\n",
    "As mentioned above, we want to include the dependencies between our LFs when training the generative model. Snorkel makes it easy to do this! `DependencySelector` runs a fast structure learning algorithm over the matrix of LF outputs to identify a set of likely dependencies. We can see that these match up with our prior knowledge. For example, it identified a \"reinforcing\" dependency between `LF_c_induced_d` and `LF_ctd_marker_induce`. Recall that we constructed the latter using the former."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "246"
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from snorkel.learning.structure import DependencySelector\n",
    "ds = DependencySelector()\n",
    "deps = ds.select(L_train, threshold=0.1)\n",
    "len(deps)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Now we'll train the generative model, using the `deps` argument to account for the learned dependencies. We'll also model LF propensity here, unlike the intro tutorial. In addition to learning the accuracies of the LFs, this also learns their likelihood of labeling an example."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Inferred cardinality: 2\n"
     ]
    }
   ],
   "source": [
    "from snorkel.learning import GenerativeModel\n",
    "\n",
    "gen_model = GenerativeModel(lf_propensity=True)\n",
    "gen_model.train(\n",
    "    L_train, deps=deps, decay=0.95, step_size=0.1/L_train.shape[0], reg_param=0.0\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [],
   "source": [
    "train_marginals = gen_model.marginals(L_train)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import matplotlib.pyplot as plt\n",
    "plt.hist(train_marginals, bins=20)\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/anaconda/envs/snorkel/lib/python3.6/site-packages/snorkel/learning/gen_learning.py:348: RuntimeWarning: invalid value encountered in double_scalars\n",
      "  \"Precision\": tp / (tp + fp),\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Accuracy</th>\n",
       "      <th>Coverage</th>\n",
       "      <th>Precision</th>\n",
       "      <th>Recall</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0.428571</td>\n",
       "      <td>0.0049</td>\n",
       "      <td>0.440000</td>\n",
       "      <td>0.002210</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>0.413793</td>\n",
       "      <td>0.0029</td>\n",
       "      <td>0.428571</td>\n",
       "      <td>0.001206</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.0003</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.000201</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>0.486111</td>\n",
       "      <td>0.0144</td>\n",
       "      <td>0.483871</td>\n",
       "      <td>0.006028</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>0.559184</td>\n",
       "      <td>0.0245</td>\n",
       "      <td>0.560748</td>\n",
       "      <td>0.012055</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>0.598790</td>\n",
       "      <td>0.0992</td>\n",
       "      <td>0.611222</td>\n",
       "      <td>0.061282</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>0.444444</td>\n",
       "      <td>0.0009</td>\n",
       "      <td>0.500000</td>\n",
       "      <td>0.000402</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>0.592593</td>\n",
       "      <td>0.0027</td>\n",
       "      <td>0.666667</td>\n",
       "      <td>0.002009</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>0.605263</td>\n",
       "      <td>0.0038</td>\n",
       "      <td>0.588235</td>\n",
       "      <td>0.002009</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>0.543307</td>\n",
       "      <td>0.0127</td>\n",
       "      <td>0.534483</td>\n",
       "      <td>0.006229</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>0.443925</td>\n",
       "      <td>0.0214</td>\n",
       "      <td>0.447619</td>\n",
       "      <td>0.009443</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>0.307692</td>\n",
       "      <td>0.0013</td>\n",
       "      <td>0.428571</td>\n",
       "      <td>0.000603</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0001</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>0.581818</td>\n",
       "      <td>0.0055</td>\n",
       "      <td>0.677419</td>\n",
       "      <td>0.004219</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>0.409091</td>\n",
       "      <td>0.0022</td>\n",
       "      <td>0.500000</td>\n",
       "      <td>0.000804</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>0.475000</td>\n",
       "      <td>0.0040</td>\n",
       "      <td>0.411765</td>\n",
       "      <td>0.001406</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>0.333333</td>\n",
       "      <td>0.0003</td>\n",
       "      <td>0.500000</td>\n",
       "      <td>0.000201</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>0.483871</td>\n",
       "      <td>0.0031</td>\n",
       "      <td>0.611111</td>\n",
       "      <td>0.002210</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>0.568627</td>\n",
       "      <td>0.0102</td>\n",
       "      <td>0.511111</td>\n",
       "      <td>0.004621</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.0002</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.000402</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>0.592554</td>\n",
       "      <td>0.1907</td>\n",
       "      <td>0.598953</td>\n",
       "      <td>0.114929</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>0.667954</td>\n",
       "      <td>0.6216</td>\n",
       "      <td>0.665585</td>\n",
       "      <td>0.412297</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.0002</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>0.609467</td>\n",
       "      <td>0.0169</td>\n",
       "      <td>0.580645</td>\n",
       "      <td>0.010850</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>0.222222</td>\n",
       "      <td>0.0009</td>\n",
       "      <td>0.250000</td>\n",
       "      <td>0.000201</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>0.450000</td>\n",
       "      <td>0.0040</td>\n",
       "      <td>0.350000</td>\n",
       "      <td>0.001406</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>0.500000</td>\n",
       "      <td>0.0002</td>\n",
       "      <td>0.500000</td>\n",
       "      <td>0.000201</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>0.500000</td>\n",
       "      <td>0.0004</td>\n",
       "      <td>0.500000</td>\n",
       "      <td>0.000201</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>0.476190</td>\n",
       "      <td>0.0021</td>\n",
       "      <td>0.333333</td>\n",
       "      <td>0.000603</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>0.500000</td>\n",
       "      <td>0.0010</td>\n",
       "      <td>0.500000</td>\n",
       "      <td>0.000603</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>0.277778</td>\n",
       "      <td>0.0018</td>\n",
       "      <td>0.250000</td>\n",
       "      <td>0.000603</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>0.500000</td>\n",
       "      <td>0.0008</td>\n",
       "      <td>0.500000</td>\n",
       "      <td>0.000201</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>0.568075</td>\n",
       "      <td>0.0213</td>\n",
       "      <td>0.627451</td>\n",
       "      <td>0.012859</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "    Accuracy  Coverage  Precision    Recall\n",
       "0   0.428571    0.0049   0.440000  0.002210\n",
       "1   0.413793    0.0029   0.428571  0.001206\n",
       "2   1.000000    0.0003   1.000000  0.000201\n",
       "3   0.486111    0.0144   0.483871  0.006028\n",
       "4   0.559184    0.0245   0.560748  0.012055\n",
       "5   0.598790    0.0992   0.611222  0.061282\n",
       "6   0.444444    0.0009   0.500000  0.000402\n",
       "7   0.592593    0.0027   0.666667  0.002009\n",
       "8   0.605263    0.0038   0.588235  0.002009\n",
       "9   0.543307    0.0127   0.534483  0.006229\n",
       "10  0.443925    0.0214   0.447619  0.009443\n",
       "11  0.307692    0.0013   0.428571  0.000603\n",
       "12  0.000000    0.0001        NaN  0.000000\n",
       "13  0.581818    0.0055   0.677419  0.004219\n",
       "14  0.409091    0.0022   0.500000  0.000804\n",
       "15  0.475000    0.0040   0.411765  0.001406\n",
       "16  0.333333    0.0003   0.500000  0.000201\n",
       "17  0.483871    0.0031   0.611111  0.002210\n",
       "18  0.568627    0.0102   0.511111  0.004621\n",
       "19  1.000000    0.0002   1.000000  0.000402\n",
       "20  0.592554    0.1907   0.598953  0.114929\n",
       "21  0.667954    0.6216   0.665585  0.412297\n",
       "22  0.000000    0.0002   0.000000  0.000000\n",
       "23  0.609467    0.0169   0.580645  0.010850\n",
       "24  0.222222    0.0009   0.250000  0.000201\n",
       "25  0.450000    0.0040   0.350000  0.001406\n",
       "26  0.500000    0.0002   0.500000  0.000201\n",
       "27  0.500000    0.0004   0.500000  0.000201\n",
       "28  0.476190    0.0021   0.333333  0.000603\n",
       "29  0.500000    0.0010   0.500000  0.000603\n",
       "30  0.277778    0.0018   0.250000  0.000603\n",
       "31  0.500000    0.0008   0.500000  0.000201\n",
       "32  0.568075    0.0213   0.627451  0.012859"
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "gen_model.learned_lf_stats()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Saved 8432 marginals\n"
     ]
    }
   ],
   "source": [
    "from snorkel.annotations import save_marginals\n",
    "save_marginals(session, L_train, train_marginals)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Checking performance against development set labels\n",
    "\n",
    "Finally, we'll run the labeler on the development set, load in some external labels, then evaluate the LF performance. The external labels are applied via a small script for convenience. It maps the document-level relation annotations found in the CDR file to mention-level labels. Note that these will not be perfect, although they are pretty good. If we wanted to keep iterating, we could use `snorkel.lf_helpers.test_LF` against the dev set, or look at some false positive and false negative candidates."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "AnnotatorLabels created: 0\n"
     ]
    }
   ],
   "source": [
    "from load_external_annotations import load_external_labels\n",
    "load_external_labels(session, ChemicalDisease, split=1, annotator='gold')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<920x1 sparse matrix of type '<class 'numpy.int64'>'\n",
       "\twith 920 stored elements in Compressed Sparse Row format>"
      ]
     },
     "execution_count": 21,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from snorkel.annotations import load_gold_labels\n",
    "L_gold_dev = load_gold_labels(session, annotator_name='gold', split=1)\n",
    "L_gold_dev"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Clearing existing...\n",
      "Running UDF...\n",
      "[========================================] 100%\n",
      "\n"
     ]
    }
   ],
   "source": [
    "L_dev = labeler.apply_existing(split=1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "========================================\n",
      "Scores (Un-adjusted)\n",
      "========================================\n",
      "Pos. class accuracy: 0.892\n",
      "Neg. class accuracy: 0.617\n",
      "Precision            0.537\n",
      "Recall               0.892\n",
      "F1                   0.671\n",
      "----------------------------------------\n",
      "TP: 273 | FP: 235 | TN: 379 | FN: 33\n",
      "========================================\n",
      "\n"
     ]
    }
   ],
   "source": [
    "_ = gen_model.error_analysis(session, L_dev, L_gold_dev)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/anaconda/envs/snorkel/lib/python3.6/site-packages/snorkel/learning/gen_learning.py:348: RuntimeWarning: invalid value encountered in double_scalars\n",
      "  \"Precision\": tp / (tp + fp),\n",
      "/anaconda/envs/snorkel/lib/python3.6/site-packages/snorkel/learning/gen_learning.py:350: RuntimeWarning: invalid value encountered in double_scalars\n",
      "  \"Accuracy\": (tp + tn) / coverage,\n",
      "/anaconda/envs/snorkel/lib/python3.6/site-packages/snorkel/annotations.py:137: RuntimeWarning: invalid value encountered in true_divide\n",
      "  ac = (tp+tn) / (tp+tn+fp+fn)\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>j</th>\n",
       "      <th>Coverage</th>\n",
       "      <th>Overlaps</th>\n",
       "      <th>Conflicts</th>\n",
       "      <th>TP</th>\n",
       "      <th>FP</th>\n",
       "      <th>FN</th>\n",
       "      <th>TN</th>\n",
       "      <th>Empirical Acc.</th>\n",
       "      <th>Learned Acc.</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>LF_c_cause_d</th>\n",
       "      <td>0</td>\n",
       "      <td>0.034783</td>\n",
       "      <td>0.033696</td>\n",
       "      <td>0.011957</td>\n",
       "      <td>22</td>\n",
       "      <td>10</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.687500</td>\n",
       "      <td>0.542857</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_c_d</th>\n",
       "      <td>1</td>\n",
       "      <td>0.020652</td>\n",
       "      <td>0.018478</td>\n",
       "      <td>0.003261</td>\n",
       "      <td>11</td>\n",
       "      <td>8</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.578947</td>\n",
       "      <td>0.411765</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_c_induced_d</th>\n",
       "      <td>2</td>\n",
       "      <td>0.002174</td>\n",
       "      <td>0.002174</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.500000</td>\n",
       "      <td>0.333333</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_c_treat_d</th>\n",
       "      <td>3</td>\n",
       "      <td>0.031522</td>\n",
       "      <td>0.031522</td>\n",
       "      <td>0.017391</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>9</td>\n",
       "      <td>20</td>\n",
       "      <td>0.689655</td>\n",
       "      <td>0.484375</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_c_treat_d_wide</th>\n",
       "      <td>4</td>\n",
       "      <td>0.077174</td>\n",
       "      <td>0.076087</td>\n",
       "      <td>0.042391</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>17</td>\n",
       "      <td>54</td>\n",
       "      <td>0.760563</td>\n",
       "      <td>0.582160</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_closer_chem</th>\n",
       "      <td>5</td>\n",
       "      <td>0.205435</td>\n",
       "      <td>0.191304</td>\n",
       "      <td>0.125000</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>55</td>\n",
       "      <td>134</td>\n",
       "      <td>0.708995</td>\n",
       "      <td>0.588978</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_closer_dis</th>\n",
       "      <td>6</td>\n",
       "      <td>0.010870</td>\n",
       "      <td>0.010870</td>\n",
       "      <td>0.006522</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>2</td>\n",
       "      <td>8</td>\n",
       "      <td>0.800000</td>\n",
       "      <td>0.333333</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_ctd_marker_c_d</th>\n",
       "      <td>7</td>\n",
       "      <td>0.018478</td>\n",
       "      <td>0.018478</td>\n",
       "      <td>0.003261</td>\n",
       "      <td>11</td>\n",
       "      <td>6</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.647059</td>\n",
       "      <td>0.500000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_ctd_marker_induce</th>\n",
       "      <td>8</td>\n",
       "      <td>0.018478</td>\n",
       "      <td>0.018478</td>\n",
       "      <td>0.006522</td>\n",
       "      <td>12</td>\n",
       "      <td>5</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.705882</td>\n",
       "      <td>0.500000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_ctd_therapy_treat</th>\n",
       "      <td>9</td>\n",
       "      <td>0.041304</td>\n",
       "      <td>0.041304</td>\n",
       "      <td>0.027174</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>8</td>\n",
       "      <td>30</td>\n",
       "      <td>0.789474</td>\n",
       "      <td>0.533333</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_ctd_unspecified_treat</th>\n",
       "      <td>10</td>\n",
       "      <td>0.057609</td>\n",
       "      <td>0.057609</td>\n",
       "      <td>0.033696</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>16</td>\n",
       "      <td>37</td>\n",
       "      <td>0.698113</td>\n",
       "      <td>0.520000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_ctd_unspecified_induce</th>\n",
       "      <td>11</td>\n",
       "      <td>0.015217</td>\n",
       "      <td>0.015217</td>\n",
       "      <td>0.004348</td>\n",
       "      <td>10</td>\n",
       "      <td>4</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.714286</td>\n",
       "      <td>0.677419</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_d_following_c</th>\n",
       "      <td>12</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_d_induced_by_c</th>\n",
       "      <td>13</td>\n",
       "      <td>0.035870</td>\n",
       "      <td>0.035870</td>\n",
       "      <td>0.017391</td>\n",
       "      <td>24</td>\n",
       "      <td>9</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.727273</td>\n",
       "      <td>0.554054</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_d_induced_by_c_tight</th>\n",
       "      <td>14</td>\n",
       "      <td>0.017391</td>\n",
       "      <td>0.017391</td>\n",
       "      <td>0.006522</td>\n",
       "      <td>11</td>\n",
       "      <td>5</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.687500</td>\n",
       "      <td>0.380952</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_d_treat_c</th>\n",
       "      <td>15</td>\n",
       "      <td>0.044565</td>\n",
       "      <td>0.036957</td>\n",
       "      <td>0.027174</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>16</td>\n",
       "      <td>25</td>\n",
       "      <td>0.609756</td>\n",
       "      <td>0.441176</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_develop_d_following_c</th>\n",
       "      <td>16</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_far_c_d</th>\n",
       "      <td>17</td>\n",
       "      <td>0.143478</td>\n",
       "      <td>0.129348</td>\n",
       "      <td>0.082609</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>29</td>\n",
       "      <td>103</td>\n",
       "      <td>0.780303</td>\n",
       "      <td>0.678571</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_far_d_c</th>\n",
       "      <td>18</td>\n",
       "      <td>0.095652</td>\n",
       "      <td>0.085870</td>\n",
       "      <td>0.056522</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>31</td>\n",
       "      <td>57</td>\n",
       "      <td>0.647727</td>\n",
       "      <td>0.608247</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_improve_before_disease</th>\n",
       "      <td>19</td>\n",
       "      <td>0.007609</td>\n",
       "      <td>0.007609</td>\n",
       "      <td>0.004348</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>6</td>\n",
       "      <td>0.857143</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_in_ctd_therapy</th>\n",
       "      <td>20</td>\n",
       "      <td>0.316304</td>\n",
       "      <td>0.271739</td>\n",
       "      <td>0.207609</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>94</td>\n",
       "      <td>197</td>\n",
       "      <td>0.676976</td>\n",
       "      <td>0.601171</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_in_ctd_marker</th>\n",
       "      <td>21</td>\n",
       "      <td>0.606522</td>\n",
       "      <td>0.479348</td>\n",
       "      <td>0.380435</td>\n",
       "      <td>304</td>\n",
       "      <td>254</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.544803</td>\n",
       "      <td>0.680698</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_in_patient_with</th>\n",
       "      <td>22</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.500000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_induce</th>\n",
       "      <td>23</td>\n",
       "      <td>0.091304</td>\n",
       "      <td>0.085870</td>\n",
       "      <td>0.031522</td>\n",
       "      <td>57</td>\n",
       "      <td>27</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.678571</td>\n",
       "      <td>0.639706</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_induce_name</th>\n",
       "      <td>24</td>\n",
       "      <td>0.003261</td>\n",
       "      <td>0.003261</td>\n",
       "      <td>0.001087</td>\n",
       "      <td>1</td>\n",
       "      <td>2</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0.333333</td>\n",
       "      <td>0.600000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_induced_other</th>\n",
       "      <td>25</td>\n",
       "      <td>0.033696</td>\n",
       "      <td>0.033696</td>\n",
       "      <td>0.016304</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>3</td>\n",
       "      <td>28</td>\n",
       "      <td>0.903226</td>\n",
       "      <td>0.472222</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_level</th>\n",
       "      <td>26</td>\n",
       "      <td>0.019565</td>\n",
       "      <td>0.015217</td>\n",
       "      <td>0.010870</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>6</td>\n",
       "      <td>12</td>\n",
       "      <td>0.666667</td>\n",
       "      <td>0.500000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_measure</th>\n",
       "      <td>27</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.333333</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_neg_d</th>\n",
       "      <td>28</td>\n",
       "      <td>0.008696</td>\n",
       "      <td>0.007609</td>\n",
       "      <td>0.003261</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>2</td>\n",
       "      <td>6</td>\n",
       "      <td>0.750000</td>\n",
       "      <td>0.576923</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_risk_d</th>\n",
       "      <td>29</td>\n",
       "      <td>0.001087</td>\n",
       "      <td>0.001087</td>\n",
       "      <td>0.001087</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.333333</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_treat_d</th>\n",
       "      <td>30</td>\n",
       "      <td>0.013043</td>\n",
       "      <td>0.013043</td>\n",
       "      <td>0.003261</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>11</td>\n",
       "      <td>0.916667</td>\n",
       "      <td>0.470588</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_uncertain</th>\n",
       "      <td>31</td>\n",
       "      <td>0.027174</td>\n",
       "      <td>0.026087</td>\n",
       "      <td>0.015217</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>2</td>\n",
       "      <td>23</td>\n",
       "      <td>0.920000</td>\n",
       "      <td>0.571429</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>LF_weak_assertions</th>\n",
       "      <td>32</td>\n",
       "      <td>0.113043</td>\n",
       "      <td>0.096739</td>\n",
       "      <td>0.057609</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>34</td>\n",
       "      <td>70</td>\n",
       "      <td>0.673077</td>\n",
       "      <td>0.592437</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                            j  Coverage  Overlaps  Conflicts   TP   FP  FN  \\\n",
       "LF_c_cause_d                0  0.034783  0.033696   0.011957   22   10   0   \n",
       "LF_c_d                      1  0.020652  0.018478   0.003261   11    8   0   \n",
       "LF_c_induced_d              2  0.002174  0.002174   0.000000    1    1   0   \n",
       "LF_c_treat_d                3  0.031522  0.031522   0.017391    0    0   9   \n",
       "LF_c_treat_d_wide           4  0.077174  0.076087   0.042391    0    0  17   \n",
       "LF_closer_chem              5  0.205435  0.191304   0.125000    0    0  55   \n",
       "LF_closer_dis               6  0.010870  0.010870   0.006522    0    0   2   \n",
       "LF_ctd_marker_c_d           7  0.018478  0.018478   0.003261   11    6   0   \n",
       "LF_ctd_marker_induce        8  0.018478  0.018478   0.006522   12    5   0   \n",
       "LF_ctd_therapy_treat        9  0.041304  0.041304   0.027174    0    0   8   \n",
       "LF_ctd_unspecified_treat   10  0.057609  0.057609   0.033696    0    0  16   \n",
       "LF_ctd_unspecified_induce  11  0.015217  0.015217   0.004348   10    4   0   \n",
       "LF_d_following_c           12  0.000000  0.000000   0.000000    0    0   0   \n",
       "LF_d_induced_by_c          13  0.035870  0.035870   0.017391   24    9   0   \n",
       "LF_d_induced_by_c_tight    14  0.017391  0.017391   0.006522   11    5   0   \n",
       "LF_d_treat_c               15  0.044565  0.036957   0.027174    0    0  16   \n",
       "LF_develop_d_following_c   16  0.000000  0.000000   0.000000    0    0   0   \n",
       "LF_far_c_d                 17  0.143478  0.129348   0.082609    0    0  29   \n",
       "LF_far_d_c                 18  0.095652  0.085870   0.056522    0    0  31   \n",
       "LF_improve_before_disease  19  0.007609  0.007609   0.004348    0    0   1   \n",
       "LF_in_ctd_therapy          20  0.316304  0.271739   0.207609    0    0  94   \n",
       "LF_in_ctd_marker           21  0.606522  0.479348   0.380435  304  254   0   \n",
       "LF_in_patient_with         22  0.000000  0.000000   0.000000    0    0   0   \n",
       "LF_induce                  23  0.091304  0.085870   0.031522   57   27   0   \n",
       "LF_induce_name             24  0.003261  0.003261   0.001087    1    2   0   \n",
       "LF_induced_other           25  0.033696  0.033696   0.016304    0    0   3   \n",
       "LF_level                   26  0.019565  0.015217   0.010870    0    0   6   \n",
       "LF_measure                 27  0.000000  0.000000   0.000000    0    0   0   \n",
       "LF_neg_d                   28  0.008696  0.007609   0.003261    0    0   2   \n",
       "LF_risk_d                  29  0.001087  0.001087   0.001087    1    0   0   \n",
       "LF_treat_d                 30  0.013043  0.013043   0.003261    0    0   1   \n",
       "LF_uncertain               31  0.027174  0.026087   0.015217    0    0   2   \n",
       "LF_weak_assertions         32  0.113043  0.096739   0.057609    0    0  34   \n",
       "\n",
       "                            TN  Empirical Acc.  Learned Acc.  \n",
       "LF_c_cause_d                 0        0.687500      0.542857  \n",
       "LF_c_d                       0        0.578947      0.411765  \n",
       "LF_c_induced_d               0        0.500000      0.333333  \n",
       "LF_c_treat_d                20        0.689655      0.484375  \n",
       "LF_c_treat_d_wide           54        0.760563      0.582160  \n",
       "LF_closer_chem             134        0.708995      0.588978  \n",
       "LF_closer_dis                8        0.800000      0.333333  \n",
       "LF_ctd_marker_c_d            0        0.647059      0.500000  \n",
       "LF_ctd_marker_induce         0        0.705882      0.500000  \n",
       "LF_ctd_therapy_treat        30        0.789474      0.533333  \n",
       "LF_ctd_unspecified_treat    37        0.698113      0.520000  \n",
       "LF_ctd_unspecified_induce    0        0.714286      0.677419  \n",
       "LF_d_following_c             0             NaN           NaN  \n",
       "LF_d_induced_by_c            0        0.727273      0.554054  \n",
       "LF_d_induced_by_c_tight      0        0.687500      0.380952  \n",
       "LF_d_treat_c                25        0.609756      0.441176  \n",
       "LF_develop_d_following_c     0             NaN      0.000000  \n",
       "LF_far_c_d                 103        0.780303      0.678571  \n",
       "LF_far_d_c                  57        0.647727      0.608247  \n",
       "LF_improve_before_disease    6        0.857143           NaN  \n",
       "LF_in_ctd_therapy          197        0.676976      0.601171  \n",
       "LF_in_ctd_marker             0        0.544803      0.680698  \n",
       "LF_in_patient_with           0             NaN      0.500000  \n",
       "LF_induce                    0        0.678571      0.639706  \n",
       "LF_induce_name               0        0.333333      0.600000  \n",
       "LF_induced_other            28        0.903226      0.472222  \n",
       "LF_level                    12        0.666667      0.500000  \n",
       "LF_measure                   0             NaN      0.333333  \n",
       "LF_neg_d                     6        0.750000      0.576923  \n",
       "LF_risk_d                    0        1.000000      0.333333  \n",
       "LF_treat_d                  11        0.916667      0.470588  \n",
       "LF_uncertain                23        0.920000      0.571429  \n",
       "LF_weak_assertions          70        0.673077      0.592437  "
      ]
     },
     "execution_count": 24,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "L_dev.lf_stats(session, L_gold_dev, gen_model.learned_lf_stats()['Accuracy'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(920,)"
      ]
     },
     "execution_count": 25,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dev_marginals = gen_model.marginals(L_dev)\n",
    "dev_marginals.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "---------- LF_in_ctd_therapy 0.0673913043478 ----------\n",
      "--------------------------------------------------\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'dobutamine'\", sentence=8843, chars=[56,65], words=[8,8]), Span(\"b'Myocardial ischemia'\", sentence=8843, chars=[0,18], words=[0,1]))\n",
      "Sentence(Document 11078231,0,b'Myocardial ischemia due to coronary artery spasm during dobutamine stress echocardiography.\\n')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'pilocarpine'\", sentence=10896, chars=[66,76], words=[10,10]), Span(\"b'impairment in word recall'\", sentence=10896, chars=[99,123], words=[15,18]))\n",
      "Sentence(Document 11022397,11,b'Pupil size at time points after administration of tropicamide and pilocarpine; scopolamine-induced impairment in word recall.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'Amiodarone'\", sentence=10774, chars=[0,9], words=[0,0]), Span(\"b'pulmonary toxicity'\", sentence=10774, chars=[11,28], words=[1,2]))\n",
      "Sentence(Document 1595783,0,b'Amiodarone pulmonary toxicity.\\n')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'corticosteroids'\", sentence=9443, chars=[107,121], words=[17,17]), Span(\"b'myopathy'\", sentence=9443, chars=[46,53], words=[7,7]))\n",
      "Sentence(Document 8665051,1,b'Occasional case reports have shown that acute myopathy may occur in patients treated with massive doses of corticosteroids.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'DX'\", sentence=8247, chars=[101,102], words=[16,16]), Span(\"b'renal toxicity'\", sentence=8247, chars=[128,141], words=[22,23]))\n",
      "Sentence(Document 7724492,9,b'These results demonstrate that, in these experimental conditions, DXNP killed less animals than free DX, despite of an enhanced renal toxicity of the former.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'Dobutamine'\", sentence=8844, chars=[0,9], words=[0,0]), Span(\"b'myocardial ischemia'\", sentence=8844, chars=[83,101], words=[14,15]))\n",
      "Sentence(Document 11078231,1,b'Dobutamine stress echocardiography (DSE) is a useful and safe provocation test for myocardial ischemia.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'doxorubicin'\", sentence=8238, chars=[24,34], words=[4,4]), Span(\"b'renal toxicity'\", sentence=8238, chars=[6,19], words=[1,2]))\n",
      "Sentence(Document 7724492,0,b'Acute renal toxicity of doxorubicin (adriamycin)-loaded cyanoacrylate nanoparticles.\\n')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'adriamycin)-loaded'\", sentence=8238, chars=[37,54], words=[6,6]), Span(\"b'renal toxicity'\", sentence=8238, chars=[6,19], words=[1,2]))\n",
      "Sentence(Document 7724492,0,b'Acute renal toxicity of doxorubicin (adriamycin)-loaded cyanoacrylate nanoparticles.\\n')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'dobutamine'\", sentence=8846, chars=[107,116], words=[19,19]), Span(\"b'myocardial ischemia'\", sentence=8846, chars=[51,69], words=[10,11]))\n",
      "Sentence(Document 11078231,3,b'The aim of the present study is to examine whether myocardial ischemia due to coronary spasm is induced by dobutamine.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'dexamethasone'\", sentence=10243, chars=[119,131], words=[17,17]), Span(\"b'multiple myeloma'\", sentence=10243, chars=[231,246], words=[31,32]))\n",
      "Sentence(Document 19274460,1,b'A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM).')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'GABA'\", sentence=9660, chars=[64,67], words=[10,10]), Span(\"b'bradycardia'\", sentence=9660, chars=[164,174], words=[24,24]))\n",
      "Sentence(Document 2894433,6,b'The data indicate that diazepam acts through the benzodiazepine-GABA-chloride channel macromolecular complex within the central nervous system to facilitate reflex bradycardia mediated through baroreceptor reflexes in response to an acute increase in arterial pressure.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'levodopa'\", sentence=10840, chars=[122,129], words=[20,20]), Span(\"b'bradykinesia'\", sentence=10840, chars=[30,41], words=[3,3]))\n",
      "Sentence(Document 15096016,6,b'Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving levodopa-induced dyskinesias.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'levodopa'\", sentence=10840, chars=[122,129], words=[20,20]), Span(\"b'rigidity'\", sentence=10840, chars=[47,54], words=[5,5]))\n",
      "Sentence(Document 15096016,6,b'Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving levodopa-induced dyskinesias.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'phenytoin'\", sentence=10744, chars=[55,63], words=[8,8]), Span(\"b'seizures'\", sentence=10744, chars=[4,11], words=[1,1]))\n",
      "Sentence(Document 2343592,3,b'All seizures were controlled with therapeutic doses of phenytoin.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'amiodarone'\", sentence=10776, chars=[26,35], words=[4,4]), Span(\"b'pulmonary toxicity'\", sentence=10776, chars=[4,21], words=[1,2]))\n",
      "Sentence(Document 1595783,2,b'The pulmonary toxicity of amiodarone is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell-mediated hypersensitivity pneumonitis.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'atropine'\", sentence=10495, chars=[98,105], words=[13,13]), Span(\"b'bradycardia'\", sentence=10495, chars=[71,81], words=[9,9]))\n",
      "Sentence(Document 17049862,4,b'Following phenytoin administration, the patient developed acute severe bradycardia, refractory to atropine and adrenaline.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'adrenaline'\", sentence=10495, chars=[111,120], words=[15,15]), Span(\"b'bradycardia'\", sentence=10495, chars=[71,81], words=[9,9]))\n",
      "Sentence(Document 17049862,4,b'Following phenytoin administration, the patient developed acute severe bradycardia, refractory to atropine and adrenaline.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'phenytoin'\", sentence=10494, chars=[12,20], words=[1,1]), Span(\"b'seizure'\", sentence=10494, chars=[80,86], words=[12,12]))\n",
      "Sentence(Document 17049862,3,b'Intravenous phenytoin was administered during the later part of the surgery for seizure prophylaxis.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'nimesulide'\", sentence=8676, chars=[61,70], words=[10,10]), Span(\"b'urticaria'\", sentence=8676, chars=[116,124], words=[17,17]))\n",
      "Sentence(Document 11694026,8,b'Taken together, our results confirm the good tolerability of nimesulide and paracetamol in patients who experienced urticaria/angioedema caused by NSAIDs.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'naloxone'\", sentence=6967, chars=[139,146], words=[22,22]), Span(\"b'hypotension'\", sentence=6967, chars=[76,86], words=[13,13]))\n",
      "Sentence(Document 1928887,3,b'We report a case of an intentional captopril overdose, manifested by marked hypotension, that resolved promptly with the administration of naloxone.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'naloxone'\", sentence=6966, chars=[22,29], words=[3,3]), Span(\"b'hypotensive'\", sentence=6966, chars=[70,80], words=[12,12]))\n",
      "Sentence(Document 1928887,2,b'The opioid antagonist naloxone has been shown to block or reverse the hypotensive actions of captopril.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'PB'\", sentence=8654, chars=[29,30], words=[4,4]), Span(\"b'liver damage'\", sentence=8654, chars=[63,74], words=[10,11]))\n",
      "Sentence(Document 17574447,5,b'Our findings illustrate that PB may be associated with chronic liver damage, which may lead to more serious and deleterious consequences.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'doxorubicin'\", sentence=10309, chars=[81,91], words=[10,10]), Span(\"b'breast cancer'\", sentence=10309, chars=[223,235], words=[27,28]))\n",
      "Sentence(Document 11230490,0,b'Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.\\n')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'doxorubicin'\", sentence=10309, chars=[141,151], words=[16,16]), Span(\"b'breast cancer'\", sentence=10309, chars=[223,235], words=[27,28]))\n",
      "Sentence(Document 11230490,0,b'Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.\\n')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'ACEI)-induced'\", sentence=7517, chars=[41,53], words=[6,6]), Span(\"b'hypertensive'\", sentence=7517, chars=[90,101], words=[14,14]))\n",
      "Sentence(Document 17285209,8,b'Angiotensin-converting enzyme inhibitor (ACEI)-induced angioedema was suspected, and anti-hypertensive medications were discontinued.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'dexamethasone'\", sentence=10250, chars=[92,104], words=[16,16]), Span(\"b'MM'\", sentence=10250, chars=[176,177], words=[27,27]))\n",
      "Sentence(Document 19274460,8,b'The results suggest that bortezomib in combination with cyclophosphamide at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'epsilon-aminocaproic acid'\", sentence=7169, chars=[46,70], words=[9,12]), Span(\"b'subarachnoid haemorrhage'\", sentence=7169, chars=[119,142], words=[25,26]))\n",
      "Sentence(Document 6674249,2,b'A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'epsilon-aminocaproic acid'\", sentence=7169, chars=[46,70], words=[9,12]), Span(\"b'SAH'\", sentence=7169, chars=[145,147], words=[28,28]))\n",
      "Sentence(Document 6674249,2,b'A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'EACA'\", sentence=7169, chars=[73,76], words=[14,14]), Span(\"b'subarachnoid haemorrhage'\", sentence=7169, chars=[119,142], words=[25,26]))\n",
      "Sentence(Document 6674249,2,b'A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'EACA'\", sentence=7169, chars=[73,76], words=[14,14]), Span(\"b'SAH'\", sentence=7169, chars=[145,147], words=[28,28]))\n",
      "Sentence(Document 6674249,2,b'A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'levodopa'\", sentence=10004, chars=[26,33], words=[5,5]), Span(\"b'dystonia'\", sentence=10004, chars=[83,90], words=[17,17]))\n",
      "Sentence(Document 458486,3,b'Tiapride had no effect on levodopa-induced early morning of \"off-period\" segmental dystonia.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'naloxone'\", sentence=6969, chars=[47,54], words=[7,7]), Span(\"b'hypotension'\", sentence=6969, chars=[75,85], words=[12,12]))\n",
      "Sentence(Document 1928887,5,b'Our experience demonstrates a possible role of naloxone in the reversal of hypotension resulting from captopril.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'Naloxone'\", sentence=6964, chars=[0,7], words=[0,0]), Span(\"b'hypotension'\", sentence=6964, chars=[21,31], words=[3,3]))\n",
      "Sentence(Document 1928887,0,b'Naloxone reversal of hypotension due to captopril overdose.\\n')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'MK-801'\", sentence=9415, chars=[196,201], words=[35,35]), Span(\"b'catalepsy'\", sentence=9415, chars=[177,185], words=[32,32]))\n",
      "Sentence(Document 11999899,10,b'Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and catalepsy, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'heparin'\", sentence=10215, chars=[53,59], words=[8,8]), Span(\"b'pelvic thrombophlebitis'\", sentence=10215, chars=[83,105], words=[12,13]))\n",
      "Sentence(Document 1255900,4,b'The disease occurred subsequent to the initiation of heparin therapy for suspected pelvic thrombophlebitis and cleared rapidly subsequent to its discontinuation.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'Calcitriol'\", sentence=8396, chars=[12,21], words=[2,2]), Span(\"b'renal failure'\", sentence=8396, chars=[101,113], words=[16,17]))\n",
      "Sentence(Document 10027919,1,b'BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'Myocet'\", sentence=10311, chars=[162,167], words=[30,30]), Span(\"b'MBC'\", sentence=10311, chars=[61,63], words=[11,11]))\n",
      "Sentence(Document 11230490,2,b'PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'doxorubicin'\", sentence=10311, chars=[189,199], words=[36,36]), Span(\"b'MBC'\", sentence=10311, chars=[61,63], words=[11,11]))\n",
      "Sentence(Document 11230490,2,b'PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'methadone'\", sentence=7335, chars=[18,26], words=[3,3]), Span(\"b'Pain'\", sentence=7335, chars=[0,3], words=[0,0]))\n",
      "Sentence(Document 11027904,0,b'Pain responses in methadone-maintained opioid abusers.\\n')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'methadone'\", sentence=7337, chars=[118,126], words=[19,19]), Span(\"b'pain'\", sentence=7337, chars=[36,39], words=[6,6]))\n",
      "Sentence(Document 11027904,2,b'This study was designed to describe pain tolerance and analgesic response in a sample of opioid addicts stabilized in methadone-maintenance (MM) treatment (n = 60) in comparison to matched nondependent control subjects (n = 60).')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'hydromorphone'\", sentence=7338, chars=[188,200], words=[38,38]), Span(\"b'pain'\", sentence=7338, chars=[88,91], words=[21,21]))\n",
      "Sentence(Document 11027904,3,b'By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'ketorolac'\", sentence=7338, chars=[244,252], words=[48,48]), Span(\"b'pain'\", sentence=7338, chars=[88,91], words=[21,21]))\n",
      "Sentence(Document 11027904,3,b'By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'mesna'\", sentence=6344, chars=[59,63], words=[10,10]), Span(\"b'hemorrhagic cystitis'\", sentence=6344, chars=[137,156], words=[19,20]))\n",
      "Sentence(Document 1545575,5,b'In contrast, two of four consecutive patients who received mesna uroprophylaxis before allogeneic bone marrow transplantation had severe hemorrhagic cystitis for at least 2 weeks.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'dexamethasone'\", sentence=10242, chars=[95,107], words=[14,14]), Span(\"b'myeloma'\", sentence=10242, chars=[166,172], words=[23,23]))\n",
      "Sentence(Document 19274460,0,b'DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.\\n')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'cisapride'\", sentence=7470, chars=[75,83], words=[14,14]), Span(\"b'gastroesophageal reflux disorder'\", sentence=7470, chars=[89,120], words=[16,18]))\n",
      "Sentence(Document 9545159,3,b'A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'mecamylamine'\", sentence=10305, chars=[54,65], words=[7,7]), Span(\"b'catalepsy'\", sentence=10305, chars=[102,110], words=[14,14]))\n",
      "Sentence(Document 11900788,4,b'Intraperitoneal administration of atropine, naloxone, mecamylamine, and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'doxorubicin'\", sentence=10310, chars=[60,70], words=[10,10]), Span(\"b'breast cancer'\", sentence=10310, chars=[298,310], words=[43,44]))\n",
      "Sentence(Document 11230490,1,b'PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'doxorubicin'\", sentence=10310, chars=[60,70], words=[10,10]), Span(\"b'MBC'\", sentence=10310, chars=[313,315], words=[46,46]))\n",
      "Sentence(Document 11230490,1,b'PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'doxorubicin'\", sentence=10310, chars=[187,197], words=[29,29]), Span(\"b'MBC'\", sentence=10310, chars=[313,315], words=[46,46]))\n",
      "Sentence(Document 11230490,1,b'PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'naloxone'\", sentence=10306, chars=[66,73], words=[8,8]), Span(\"b'catalepsy'\", sentence=10306, chars=[90,98], words=[11,11]))\n",
      "Sentence(Document 11900788,5,b'Intracerebroventricular injection of atropine, hexamethonium, and naloxone also decreased catalepsy induced by morphine plus nicotine.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'dopamine'\", sentence=10005, chars=[128,135], words=[21,21]), Span(\"b'dyskinesias'\", sentence=10005, chars=[63,73], words=[11,11]))\n",
      "Sentence(Document 458486,4,b'These results fail to support the notion that levodopa-induced dyskinesias are caused by overstimulation of a separate group of dopamine receptors.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'warfarin'\", sentence=7034, chars=[151,158], words=[26,26]), Span(\"b'haemorrhage'\", sentence=7034, chars=[35,45], words=[7,7]))\n",
      "Sentence(Document 19058474,1,b'We report a case of fatal internal haemorrhage in an elderly man who consumed only cranberry juice for two weeks while maintaining his usual dosage of warfarin.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'METH'\", sentence=6432, chars=[53,56], words=[8,8]), Span(\"b'hyperactivity'\", sentence=6432, chars=[66,78], words=[11,11]))\n",
      "Sentence(Document 16192988,3,b'This increase in aggressiveness was not secondary to METH-induced hyperactivity.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'naloxone'\", sentence=6968, chars=[96,103], words=[17,17]), Span(\"b'hypotension'\", sentence=6968, chars=[71,81], words=[14,14]))\n",
      "Sentence(Document 1928887,4,b'To our knowledge, this is the first reported case of captopril-induced hypotension treated with naloxone.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'D-penicillamine'\", sentence=9674, chars=[95,109], words=[15,17]), Span(\"b'localized scleroderma'\", sentence=9674, chars=[51,71], words=[9,10]))\n",
      "Sentence(Document 2334179,3,b'Case reports of 11 patients with severe, extensive localized scleroderma who were treated with D-penicillamine are summarized in this article.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'amiodarone'\", sentence=10777, chars=[42,51], words=[6,6]), Span(\"b'pulmonary toxicity'\", sentence=10777, chars=[61,78], words=[9,10]))\n",
      "Sentence(Document 1595783,3,b'The clinical and radiographic features of amiodarone-induced pulmonary toxicity are characteristic but nonspecific.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'MK-801'\", sentence=9414, chars=[2,7], words=[1,1]), Span(\"b'catalepsy'\", sentence=9414, chars=[51,59], words=[11,11]))\n",
      "Sentence(Document 11999899,9,b'. MK-801 (0.1 mg/kg) administration attenuated the catalepsy and tremor induced by reserpine.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'lithium'\", sentence=10651, chars=[93,99], words=[18,18]), Span(\"b'bipolar disorder'\", sentence=10651, chars=[66,81], words=[15,16]))\n",
      "Sentence(Document 10354657,5,b\"PATIENTS: One hundred and one patients (28 men and 73 women) with bipolar disorder receiving lithium maintenance therapy ranging from 1 year's to 32 years' duration.\")\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'tamoxifen'\", sentence=9508, chars=[61,69], words=[9,9]), Span(\"b'breast cancer'\", sentence=9508, chars=[132,144], words=[25,26]))\n",
      "Sentence(Document 14745746,3,b'Patients participating in a randomised trial of anastrozole, tamoxifen alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'Ca(2+)](i'\", sentence=8552, chars=[251,259], words=[39,39]), Span(\"b'arrhythmia'\", sentence=8552, chars=[164,173], words=[23,23]))\n",
      "Sentence(Document 19721134,3,b'The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'Ca(2+)](i'\", sentence=8552, chars=[251,259], words=[39,39]), Span(\"b'arrhythmic'\", sentence=8552, chars=[217,226], words=[32,32]))\n",
      "Sentence(Document 19721134,3,b'The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'doxorubicin'\", sentence=8239, chars=[6,16], words=[1,1]), Span(\"b'renal toxicity'\", sentence=8239, chars=[45,58], words=[8,9]))\n",
      "Sentence(Document 7724492,1,b'Acute doxorubicin-loaded nanoparticle (DXNP) renal toxicity was explored in both normal rats and rats with experimental glomerulonephritis.')\n",
      "-----\n",
      "---------- LF_far_c_d 0.0347826086957 ----------\n",
      "--------------------------------------------------\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'lindane'\", sentence=9136, chars=[150,156], words=[22,22]), Span(\"b'toxicity'\", sentence=9136, chars=[294,301], words=[44,44]))\n",
      "Sentence(Document 12842176,7,b'Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'lindane'\", sentence=9136, chars=[174,180], words=[25,25]), Span(\"b'toxicity'\", sentence=9136, chars=[294,301], words=[44,44]))\n",
      "Sentence(Document 12842176,7,b'Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'anthracyclines'\", sentence=10282, chars=[13,26], words=[3,3]), Span(\"b'cardiac toxicity'\", sentence=10282, chars=[207,222], words=[30,31]))\n",
      "Sentence(Document 15897593,1,b'PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'daunorubicin'\", sentence=10282, chars=[28,39], words=[4,4]), Span(\"b'myelosuppression'\", sentence=10282, chars=[186,201], words=[28,28]))\n",
      "Sentence(Document 15897593,1,b'PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'doxorubicin'\", sentence=10282, chars=[45,55], words=[6,6]), Span(\"b'myelosuppression'\", sentence=10282, chars=[186,201], words=[28,28]))\n",
      "Sentence(Document 15897593,1,b'PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'doxorubicin'\", sentence=10282, chars=[45,55], words=[6,6]), Span(\"b'cardiac toxicity'\", sentence=10282, chars=[207,222], words=[30,31]))\n",
      "Sentence(Document 15897593,1,b'PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'doxorubicin'\", sentence=10309, chars=[81,91], words=[10,10]), Span(\"b'breast cancer'\", sentence=10309, chars=[223,235], words=[27,28]))\n",
      "Sentence(Document 11230490,0,b'Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.\\n')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'angiotensin II'\", sentence=10436, chars=[61,74], words=[10,11]), Span(\"b'hypertension'\", sentence=10436, chars=[210,221], words=[36,36]))\n",
      "Sentence(Document 8841157,1,b'OBJECTIVE: To compare the antihypertensive efficacy of a new angiotensin II antagonist, valsartan, with a reference therapy, amlodipine. METHODS: One hundred sixty-eight adult outpatients with mild to moderate hypertension were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'heroin'\", sentence=9778, chars=[3,8], words=[1,1]), Span(\"b'TdP'\", sentence=9778, chars=[177,179], words=[28,28]))\n",
      "Sentence(Document 17344330,3,b'As heroin addicts sometimes faint while using illicit drugs, doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of TdP in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of methadone.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'steroid'\", sentence=9455, chars=[106,112], words=[18,18]), Span(\"b'necrosis'\", sentence=9455, chars=[252,259], words=[40,40]))\n",
      "Sentence(Document 8665051,13,b'ATPase staining of the diaphragm, scalenus medius, and gastrocnemius showed type IIb fiber atrophy in the steroid groups and also diaphragmatic type IIa atrophy with T, whereas histologic examinations revealed a normal muscular pattern with absence of necrosis.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'Myocet'\", sentence=10311, chars=[162,167], words=[30,30]), Span(\"b'toxicity'\", sentence=10311, chars=[319,326], words=[63,63]))\n",
      "Sentence(Document 11230490,2,b'PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'doxorubicin'\", sentence=10311, chars=[189,199], words=[36,36]), Span(\"b'toxicity'\", sentence=10311, chars=[319,326], words=[63,63]))\n",
      "Sentence(Document 11230490,2,b'PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'malondialdehyde'\", sentence=10948, chars=[7,21], words=[1,1]), Span(\"b'ischemia'\", sentence=10948, chars=[136,143], words=[28,28]))\n",
      "Sentence(Document 7710775,5,b'Plasma malondialdehyde, which was present in minimal amount at zero time (0.058 mumol/liter plasma; SD 0.015), increased after 5 min of ischemia, resulting in a fivefold increase after 30 min of carotid occlusion (0.298 mumol/liter plasma; SD 0.078).')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'Myocet'\", sentence=10310, chars=[30,35], words=[5,5]), Span(\"b'cardiotoxicity'\", sentence=10310, chars=[199,212], words=[30,30]))\n",
      "Sentence(Document 11230490,1,b'PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'doxorubicin'\", sentence=10310, chars=[60,70], words=[10,10]), Span(\"b'cardiotoxicity'\", sentence=10310, chars=[199,212], words=[30,30]))\n",
      "Sentence(Document 11230490,1,b'PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'doxorubicin'\", sentence=10310, chars=[60,70], words=[10,10]), Span(\"b'breast cancer'\", sentence=10310, chars=[298,310], words=[43,44]))\n",
      "Sentence(Document 11230490,1,b'PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'doxorubicin'\", sentence=10310, chars=[60,70], words=[10,10]), Span(\"b'MBC'\", sentence=10310, chars=[313,315], words=[46,46]))\n",
      "Sentence(Document 11230490,1,b'PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'doxorubicin'\", sentence=10310, chars=[187,197], words=[29,29]), Span(\"b'MBC'\", sentence=10310, chars=[313,315], words=[46,46]))\n",
      "Sentence(Document 11230490,1,b'PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'daunorubicin'\", sentence=10288, chars=[85,96], words=[12,12]), Span(\"b'myelosuppression'\", sentence=10288, chars=[226,241], words=[32,32]))\n",
      "Sentence(Document 15897593,7,b'RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'daunorubicin'\", sentence=10288, chars=[85,96], words=[12,12]), Span(\"b'cytotoxicity'\", sentence=10288, chars=[274,285], words=[41,41]))\n",
      "Sentence(Document 15897593,7,b'RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'etoposide'\", sentence=10288, chars=[102,110], words=[14,14]), Span(\"b'myelosuppression'\", sentence=10288, chars=[226,241], words=[32,32]))\n",
      "Sentence(Document 15897593,7,b'RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'etoposide'\", sentence=10288, chars=[102,110], words=[14,14]), Span(\"b'cytotoxicity'\", sentence=10288, chars=[274,285], words=[41,41]))\n",
      "Sentence(Document 15897593,7,b'RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'malondialdehyde'\", sentence=10952, chars=[52,66], words=[8,8]), Span(\"b'ischemic'\", sentence=10952, chars=[195,202], words=[30,30]))\n",
      "Sentence(Document 7710775,9,b'The present data indicate that the determination of malondialdehyde, oxypurines, and nucleosides in peripheral blood, may be used to monitor the metabolic alterations of tissues occurring during ischemic phenomena.(ABSTRACT TRUNCATED AT 250 WORDS)')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'D-Penicillamine'\", sentence=9679, chars=[0,14], words=[0,2]), Span(\"b'renal insufficiency'\", sentence=9679, chars=[125,143], words=[20,21]))\n",
      "Sentence(Document 2334179,8,b'D-Penicillamine caused nephrotic syndrome in 1 patient and milder reversible proteinuria in 3 other patients; none developed renal insufficiency.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'steroids'\", sentence=9457, chars=[64,71], words=[14,14]), Span(\"b'atrophy'\", sentence=9457, chars=[183,189], words=[34,34]))\n",
      "Sentence(Document 8665051,15,b'We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'steroids'\", sentence=9457, chars=[64,71], words=[14,14]), Span(\"b'atrophy'\", sentence=9457, chars=[324,330], words=[60,60]))\n",
      "Sentence(Document 8665051,15,b'We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'steroids'\", sentence=9457, chars=[64,71], words=[14,14]), Span(\"b'muscle necrosis'\", sentence=9457, chars=[294,308], words=[52,53]))\n",
      "Sentence(Document 8665051,15,b'We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'steroids'\", sentence=9457, chars=[143,150], words=[29,29]), Span(\"b'atrophy'\", sentence=9457, chars=[324,330], words=[60,60]))\n",
      "Sentence(Document 8665051,15,b'We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'steroids'\", sentence=9457, chars=[143,150], words=[29,29]), Span(\"b'muscle necrosis'\", sentence=9457, chars=[294,308], words=[52,53]))\n",
      "Sentence(Document 8665051,15,b'We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'lithium'\", sentence=10648, chars=[53,59], words=[9,9]), Span(\"b'thyroid disease'\", sentence=10648, chars=[160,174], words=[32,33]))\n",
      "Sentence(Document 10354657,2,b'These were evaluated with respect to the duration of lithium therapy, age, sex, and family history (whether or not the patient had a first-degree relative with thyroid disease).')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'reserpine'\", sentence=9416, chars=[24,32], words=[4,4]), Span(\"b'tardive dsykinesia'\", sentence=9416, chars=[172,189], words=[28,29]))\n",
      "Sentence(Document 11999899,11,b'These results show that reserpine produces different and abnormal movements, which are related to dose and schedule employed and can be considered as parkinsonian-like and tardive dsykinesia signs.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'doxorubicin'\", sentence=8239, chars=[6,16], words=[1,1]), Span(\"b'glomerulonephritis'\", sentence=8239, chars=[120,137], words=[20,20]))\n",
      "Sentence(Document 7724492,1,b'Acute doxorubicin-loaded nanoparticle (DXNP) renal toxicity was explored in both normal rats and rats with experimental glomerulonephritis.')\n",
      "-----\n",
      "---------- LF_closer_chem 0.0336956521739 ----------\n",
      "--------------------------------------------------\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'Li'\", sentence=6777, chars=[117,118], words=[24,24]), Span(\"b'akathisia'\", sentence=6777, chars=[17,25], words=[3,3]))\n",
      "Sentence(Document 17042884,10,b'The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'Li'\", sentence=6777, chars=[141,142], words=[33,33]), Span(\"b'akathisia'\", sentence=6777, chars=[17,25], words=[3,3]))\n",
      "Sentence(Document 17042884,10,b'The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'lindane'\", sentence=9136, chars=[150,156], words=[22,22]), Span(\"b'toxicity'\", sentence=9136, chars=[294,301], words=[44,44]))\n",
      "Sentence(Document 12842176,7,b'Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'lindane'\", sentence=9136, chars=[174,180], words=[25,25]), Span(\"b'toxicity'\", sentence=9136, chars=[294,301], words=[44,44]))\n",
      "Sentence(Document 12842176,7,b'Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'anthracycline'\", sentence=6533, chars=[37,49], words=[6,6]), Span(\"b'cardiomyopathy'\", sentence=6533, chars=[112,125], words=[18,18]))\n",
      "Sentence(Document 9848575,0,b'Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs.\\n')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'etoposide'\", sentence=10281, chars=[84,92], words=[11,11]), Span(\"b'myelosuppression'\", sentence=10281, chars=[29,44], words=[3,3]))\n",
      "Sentence(Document 15897593,0,b'Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.\\n')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'daunorubicin'\", sentence=10281, chars=[98,109], words=[13,13]), Span(\"b'myelosuppression'\", sentence=10281, chars=[29,44], words=[3,3]))\n",
      "Sentence(Document 15897593,0,b'Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.\\n')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'doxorubicin'\", sentence=10281, chars=[119,129], words=[16,16]), Span(\"b'myelosuppression'\", sentence=10281, chars=[29,44], words=[3,3]))\n",
      "Sentence(Document 15897593,0,b'Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.\\n')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'penicillin'\", sentence=9950, chars=[134,143], words=[28,28]), Span(\"b'acute renal failure'\", sentence=9950, chars=[66,84], words=[12,14]))\n",
      "Sentence(Document 4069770,1,b'The clinical and autopsy findings in a premature baby who died of acute renal failure after therapy with gentamicin (5 mg/kg/day) and penicillin are presented.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'6-OHDA'\", sentence=6992, chars=[174,179], words=[33,33]), Span(\"b'PD'\", sentence=6992, chars=[76,77], words=[13,13]))\n",
      "Sentence(Document 19940105,6,b'In a more complex task commonly used to evaluate major akinetic symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'paracetamol'\", sentence=8670, chars=[77,87], words=[11,11]), Span(\"b'urticaria'\", sentence=8670, chars=[183,191], words=[30,30]))\n",
      "Sentence(Document 11694026,2,b'In this study we investigated tolerability and reliability of nimesulide and paracetamol in a very large number of patients with an exclusive well-documented history of NSAID-induced urticaria/angioedema.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'cyclophosphamide'\", sentence=10319, chars=[204,219], words=[28,28]), Span(\"b'cardiotoxicity'\", sentence=10319, chars=[91,104], words=[12,12]))\n",
      "Sentence(Document 11230490,10,b'CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'Myocet'\", sentence=10311, chars=[162,167], words=[30,30]), Span(\"b'toxicity'\", sentence=10311, chars=[319,326], words=[63,63]))\n",
      "Sentence(Document 11230490,2,b'PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'doxorubicin'\", sentence=10311, chars=[189,199], words=[36,36]), Span(\"b'toxicity'\", sentence=10311, chars=[319,326], words=[63,63]))\n",
      "Sentence(Document 11230490,2,b'PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'paracetamol'\", sentence=8668, chars=[31,41], words=[4,4]), Span(\"b'urticaria'\", sentence=8668, chars=[74,82], words=[11,11]))\n",
      "Sentence(Document 11694026,0,b'Tolerability of nimesulide and paracetamol in patients with NSAID-induced urticaria/angioedema.\\n')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'paracetamol'\", sentence=8672, chars=[72,82], words=[12,12]), Span(\"b'urticaria'\", sentence=8672, chars=[144,152], words=[25,25]))\n",
      "Sentence(Document 11694026,4,b'A single-placebo-controlled oral challenge procedure with nimesulide or paracetamol was applied to 829 patients with a history of NSAID-induced urticaria/angioedema.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'DVP'\", sentence=6775, chars=[101,103], words=[25,25]), Span(\"b'EPS'\", sentence=6775, chars=[11,13], words=[2,2]))\n",
      "Sentence(Document 17042884,8,b'Similarly, EPS-related adverse events with QTP + Li/DVP (21.4%) were no different than with PBO + Li/DVP (19.2%).')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'Myocet'\", sentence=10310, chars=[30,35], words=[5,5]), Span(\"b'cardiotoxicity'\", sentence=10310, chars=[199,212], words=[30,30]))\n",
      "Sentence(Document 11230490,1,b'PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'doxorubicin'\", sentence=10310, chars=[60,70], words=[10,10]), Span(\"b'cardiotoxicity'\", sentence=10310, chars=[199,212], words=[30,30]))\n",
      "Sentence(Document 11230490,1,b'PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'cyclophosphamide'\", sentence=10310, chars=[148,163], words=[26,26]), Span(\"b'cardiotoxicity'\", sentence=10310, chars=[199,212], words=[30,30]))\n",
      "Sentence(Document 11230490,1,b'PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'daunorubicin'\", sentence=10288, chars=[85,96], words=[12,12]), Span(\"b'myelosuppression'\", sentence=10288, chars=[47,62], words=[7,7]))\n",
      "Sentence(Document 15897593,7,b'RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'daunorubicin'\", sentence=10288, chars=[85,96], words=[12,12]), Span(\"b'myelosuppression'\", sentence=10288, chars=[226,241], words=[32,32]))\n",
      "Sentence(Document 15897593,7,b'RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'daunorubicin'\", sentence=10288, chars=[85,96], words=[12,12]), Span(\"b'cytotoxicity'\", sentence=10288, chars=[274,285], words=[41,41]))\n",
      "Sentence(Document 15897593,7,b'RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'etoposide'\", sentence=10288, chars=[102,110], words=[14,14]), Span(\"b'myelosuppression'\", sentence=10288, chars=[47,62], words=[7,7]))\n",
      "Sentence(Document 15897593,7,b'RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'etoposide'\", sentence=10288, chars=[102,110], words=[14,14]), Span(\"b'myelosuppression'\", sentence=10288, chars=[226,241], words=[32,32]))\n",
      "Sentence(Document 15897593,7,b'RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'etoposide'\", sentence=10288, chars=[102,110], words=[14,14]), Span(\"b'cytotoxicity'\", sentence=10288, chars=[274,285], words=[41,41]))\n",
      "Sentence(Document 15897593,7,b'RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'doxorubicin'\", sentence=10288, chars=[292,302], words=[43,43]), Span(\"b'myelosuppression'\", sentence=10288, chars=[47,62], words=[7,7]))\n",
      "Sentence(Document 15897593,7,b'RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'doxorubicin'\", sentence=10288, chars=[292,302], words=[43,43]), Span(\"b'myelosuppression'\", sentence=10288, chars=[226,241], words=[32,32]))\n",
      "Sentence(Document 15897593,7,b'RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'dopamine'\", sentence=10005, chars=[128,135], words=[21,21]), Span(\"b'dyskinesias'\", sentence=10005, chars=[63,73], words=[11,11]))\n",
      "Sentence(Document 458486,4,b'These results fail to support the notion that levodopa-induced dyskinesias are caused by overstimulation of a separate group of dopamine receptors.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'ouabain'\", sentence=8552, chars=[295,301], words=[46,46]), Span(\"b'ventricular tachycardia'\", sentence=8552, chars=[114,136], words=[17,18]))\n",
      "Sentence(Document 19721134,3,b'The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'doxorubicin'\", sentence=6538, chars=[131,141], words=[22,22]), Span(\"b'cardiotoxic'\", sentence=6538, chars=[36,46], words=[5,5]))\n",
      "Sentence(Document 9848575,5,b'To examine a possibly deteriorating cardiotoxic effect of SM-5887, low-grade cardiomyopathy was induced in dogs by four courses of doxorubicin (1.5 mg/kg).')\n",
      "-----\n",
      "---------- LF_in_ctd_marker 0.0336956521739 ----------\n",
      "--------------------------------------------------\n",
      "GT: 1 LF: 1 Gen: -1\n",
      "ChemicalDisease(Span(\"b'Haloperidol'\", sentence=6779, chars=[0,10], words=[0,0]), Span(\"b'extrapyramidal syndrome'\", sentence=6779, chars=[131,153], words=[27,28]))\n",
      "Sentence(Document 17042884,12,b'Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.')\n",
      "-----\n",
      "GT: 1 LF: 1 Gen: -1\n",
      "ChemicalDisease(Span(\"b'sulphasalazine'\", sentence=10488, chars=[22,35], words=[3,3]), Span(\"b'pleural effusions'\", sentence=10488, chars=[150,166], words=[27,28]))\n",
      "Sentence(Document 19203554,5,b'Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.')\n",
      "-----\n",
      "GT: 1 LF: 1 Gen: -1\n",
      "ChemicalDisease(Span(\"b'sulphasalazine'\", sentence=10488, chars=[22,35], words=[3,3]), Span(\"b'pleural effusion'\", sentence=10488, chars=[296,311], words=[54,55]))\n",
      "Sentence(Document 19203554,5,b'Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.')\n",
      "-----\n",
      "GT: 1 LF: 1 Gen: -1\n",
      "ChemicalDisease(Span(\"b'Lithium'\", sentence=6778, chars=[0,6], words=[0,0]), Span(\"b'tremor'\", sentence=6778, chars=[75,80], words=[14,14]))\n",
      "Sentence(Document 17042884,11,b'Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.')\n",
      "-----\n",
      "GT: 1 LF: 1 Gen: -1\n",
      "ChemicalDisease(Span(\"b'Lithium'\", sentence=6778, chars=[0,6], words=[0,0]), Span(\"b'tremor'\", sentence=6778, chars=[125,130], words=[25,25]))\n",
      "Sentence(Document 17042884,11,b'Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.')\n",
      "-----\n",
      "GT: 1 LF: 1 Gen: -1\n",
      "ChemicalDisease(Span(\"b'lithium'\", sentence=6778, chars=[168,174], words=[34,34]), Span(\"b'tremor'\", sentence=6778, chars=[75,80], words=[14,14]))\n",
      "Sentence(Document 17042884,11,b'Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.')\n",
      "-----\n",
      "GT: 1 LF: 1 Gen: -1\n",
      "ChemicalDisease(Span(\"b'lithium'\", sentence=6778, chars=[251,257], words=[48,48]), Span(\"b'tremor'\", sentence=6778, chars=[75,80], words=[14,14]))\n",
      "Sentence(Document 17042884,11,b'Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.')\n",
      "-----\n",
      "GT: 1 LF: 1 Gen: -1\n",
      "ChemicalDisease(Span(\"b'lithium'\", sentence=6778, chars=[251,257], words=[48,48]), Span(\"b'tremor'\", sentence=6778, chars=[125,130], words=[25,25]))\n",
      "Sentence(Document 17042884,11,b'Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.')\n",
      "-----\n",
      "GT: 1 LF: 1 Gen: -1\n",
      "ChemicalDisease(Span(\"b'milrinone'\", sentence=9619, chars=[186,194], words=[26,26]), Span(\"b'hypotension'\", sentence=9619, chars=[50,60], words=[7,7]))\n",
      "Sentence(Document 10728962,2,b'In patients with decompensated heart failure with hypotension after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone.')\n",
      "-----\n",
      "GT: 1 LF: 1 Gen: -1\n",
      "ChemicalDisease(Span(\"b'lindane'\", sentence=9136, chars=[48,54], words=[7,7]), Span(\"b'convulsions'\", sentence=9136, chars=[100,110], words=[15,15]))\n",
      "Sentence(Document 12842176,7,b'Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.')\n",
      "-----\n",
      "GT: 1 LF: 1 Gen: -1\n",
      "ChemicalDisease(Span(\"b'lindane'\", sentence=9136, chars=[150,156], words=[22,22]), Span(\"b'convulsions'\", sentence=9136, chars=[100,110], words=[15,15]))\n",
      "Sentence(Document 12842176,7,b'Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.')\n",
      "-----\n",
      "GT: 1 LF: 1 Gen: -1\n",
      "ChemicalDisease(Span(\"b'lindane'\", sentence=9136, chars=[174,180], words=[25,25]), Span(\"b'convulsions'\", sentence=9136, chars=[100,110], words=[15,15]))\n",
      "Sentence(Document 12842176,7,b'Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.')\n",
      "-----\n",
      "GT: 1 LF: 1 Gen: -1\n",
      "ChemicalDisease(Span(\"b'diazepam'\", sentence=9658, chars=[42,49], words=[6,6]), Span(\"b'bradycardia'\", sentence=9658, chars=[163,173], words=[27,27]))\n",
      "Sentence(Document 2894433,4,b'Intravenous pretreatment of the rats with diazepam, although causing no change in the adrenaline-induced pressor effect, did enhance the adrenaline-induced reflex bradycardia.')\n",
      "-----\n",
      "GT: 1 LF: 1 Gen: -1\n",
      "ChemicalDisease(Span(\"b'lindane'\", sentence=9135, chars=[177,183], words=[29,29]), Span(\"b'convulsions'\", sentence=9135, chars=[384,394], words=[63,63]))\n",
      "Sentence(Document 12842176,6,b'Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.')\n",
      "-----\n",
      "GT: 1 LF: 1 Gen: -1\n",
      "ChemicalDisease(Span(\"b'lindane'\", sentence=9135, chars=[368,374], words=[61,61]), Span(\"b'convulsions'\", sentence=9135, chars=[193,203], words=[31,31]))\n",
      "Sentence(Document 12842176,6,b'Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.')\n",
      "-----\n",
      "GT: 1 LF: 1 Gen: -1\n",
      "ChemicalDisease(Span(\"b'BHA'\", sentence=6308, chars=[19,21], words=[4,4]), Span(\"b'forestomach tumors'\", sentence=6308, chars=[211,228], words=[37,38]))\n",
      "Sentence(Document 3131282,3,b'In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.')\n",
      "-----\n",
      "GT: 1 LF: 1 Gen: -1\n",
      "ChemicalDisease(Span(\"b'reserpine'\", sentence=9415, chars=[18,26], words=[2,2]), Span(\"b'catalepsy'\", sentence=9415, chars=[177,185], words=[32,32]))\n",
      "Sentence(Document 11999899,10,b'Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and catalepsy, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.')\n",
      "-----\n",
      "GT: 1 LF: 1 Gen: -1\n",
      "ChemicalDisease(Span(\"b'reserpine'\", sentence=9415, chars=[272,280], words=[52,52]), Span(\"b'catalepsy'\", sentence=9415, chars=[177,185], words=[32,32]))\n",
      "Sentence(Document 11999899,10,b'Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and catalepsy, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.')\n",
      "-----\n",
      "GT: 1 LF: 1 Gen: -1\n",
      "ChemicalDisease(Span(\"b'paracetamol'\", sentence=8670, chars=[77,87], words=[11,11]), Span(\"b'angioedema'\", sentence=8670, chars=[193,202], words=[32,32]))\n",
      "Sentence(Document 11694026,2,b'In this study we investigated tolerability and reliability of nimesulide and paracetamol in a very large number of patients with an exclusive well-documented history of NSAID-induced urticaria/angioedema.')\n",
      "-----\n",
      "GT: 1 LF: 1 Gen: -1\n",
      "ChemicalDisease(Span(\"b'Calcitriol'\", sentence=8396, chars=[12,21], words=[2,2]), Span(\"b'hypercalcemia'\", sentence=8396, chars=[152,164], words=[24,24]))\n",
      "Sentence(Document 10027919,1,b'BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.')\n",
      "-----\n",
      "GT: 1 LF: 1 Gen: -1\n",
      "ChemicalDisease(Span(\"b'Nicotine'\", sentence=10301, chars=[0,7], words=[0,0]), Span(\"b'catalepsy'\", sentence=10301, chars=[42,50], words=[6,6]))\n",
      "Sentence(Document 11900788,0,b'Nicotine potentiation of morphine-induced catalepsy in mice.\\n')\n",
      "-----\n",
      "GT: 1 LF: 1 Gen: -1\n",
      "ChemicalDisease(Span(\"b'milrinone'\", sentence=9618, chars=[48,56], words=[7,7]), Span(\"b'hypotension'\", sentence=9618, chars=[160,170], words=[23,23]))\n",
      "Sentence(Document 10728962,1,b'The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension.')\n",
      "-----\n",
      "GT: 1 LF: 1 Gen: -1\n",
      "ChemicalDisease(Span(\"b'paracetamol'\", sentence=8672, chars=[72,82], words=[12,12]), Span(\"b'angioedema'\", sentence=8672, chars=[154,163], words=[27,27]))\n",
      "Sentence(Document 11694026,4,b'A single-placebo-controlled oral challenge procedure with nimesulide or paracetamol was applied to 829 patients with a history of NSAID-induced urticaria/angioedema.')\n",
      "-----\n",
      "GT: 1 LF: 1 Gen: -1\n",
      "ChemicalDisease(Span(\"b'glyceryl trinitrate'\", sentence=8835, chars=[107,125], words=[19,20]), Span(\"b'headache'\", sentence=8835, chars=[74,81], words=[13,13]))\n",
      "Sentence(Document 11284996,2,b'In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.')\n",
      "-----\n",
      "GT: 1 LF: 1 Gen: -1\n",
      "ChemicalDisease(Span(\"b'GTN'\", sentence=8835, chars=[128,130], words=[22,22]), Span(\"b'headache'\", sentence=8835, chars=[74,81], words=[13,13]))\n",
      "Sentence(Document 11284996,2,b'In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.')\n",
      "-----\n",
      "GT: 1 LF: 1 Gen: -1\n",
      "ChemicalDisease(Span(\"b'Vasopressin'\", sentence=9617, chars=[0,10], words=[0,0]), Span(\"b'hypotension'\", sentence=9617, chars=[50,60], words=[8,8]))\n",
      "Sentence(Document 10728962,0,b'Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure.\\n')\n",
      "-----\n",
      "GT: 1 LF: 1 Gen: -1\n",
      "ChemicalDisease(Span(\"b'estrogens'\", sentence=10964, chars=[27,35], words=[4,4]), Span(\"b'endometrial carcinoma'\", sentence=10964, chars=[110,130], words=[17,18]))\n",
      "Sentence(Document 7421734,3,b'Young women on replacement estrogens for ovarian failure after cancer therapy may also have increased risk of endometrial carcinoma and should be examined periodically.')\n",
      "-----\n",
      "GT: 1 LF: 1 Gen: -1\n",
      "ChemicalDisease(Span(\"b'haloperidol'\", sentence=6776, chars=[73,83], words=[12,12]), Span(\"b'EPS'\", sentence=6776, chars=[213,215], words=[38,38]))\n",
      "Sentence(Document 17042884,9,b'Adverse events related to EPS occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.')\n",
      "-----\n",
      "GT: 1 LF: 1 Gen: -1\n",
      "ChemicalDisease(Span(\"b'estrogens'\", sentence=10963, chars=[113,121], words=[16,16]), Span(\"b'endometrial cancer'\", sentence=10963, chars=[169,186], words=[25,26]))\n",
      "Sentence(Document 7421734,2,b'She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease, and received exogenous estrogens, a treatment implicated in the development of endometrial cancer in menopausal women.')\n",
      "-----\n",
      "GT: 1 LF: 1 Gen: -1\n",
      "ChemicalDisease(Span(\"b'fluvoxamine'\", sentence=10461, chars=[26,36], words=[4,4]), Span(\"b'hyperactivity'\", sentence=10461, chars=[129,141], words=[25,25]))\n",
      "Sentence(Document 2576810,2,b'A repeated treatment with fluvoxamine (twice daily for 14 days) potentiated in mice and in rats (weaker) the amphetamine-induced hyperactivity.')\n",
      "-----\n",
      "GT: 1 LF: 1 Gen: -1\n",
      "ChemicalDisease(Span(\"b'nicotine'\", sentence=10308, chars=[138,145], words=[22,22]), Span(\"b'catalepsy'\", sentence=10308, chars=[31,39], words=[5,5]))\n",
      "Sentence(Document 11900788,7,b'It was concluded that morphine catalepsy can be elicited by opioid and cholinergic receptors, and the potentiation of morphine induced by nicotine may also be mediated through cholinergic receptor mechanisms.')\n",
      "-----\n",
      "---------- LF_far_d_c 0.0184782608696 ----------\n",
      "--------------------------------------------------\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'lithium'\", sentence=10655, chars=[228,234], words=[38,38]), Span(\"b'thyroid illness'\", sentence=10655, chars=[55,69], words=[9,10]))\n",
      "Sentence(Document 10354657,9,b'All patients having first-degree relatives affected by thyroid illness had accelerated onset of hypothyroidism (3.7 years after onset of lithium therapy) compared with patients without a family history (8.6 years after onset of lithium therapy).')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'Li'\", sentence=6777, chars=[141,142], words=[33,33]), Span(\"b'akathisia'\", sentence=6777, chars=[17,25], words=[3,3]))\n",
      "Sentence(Document 17042884,10,b'The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'epinephrine'\", sentence=9646, chars=[139,149], words=[23,23]), Span(\"b'muscle damage'\", sentence=9646, chars=[15,27], words=[3,4]))\n",
      "Sentence(Document 4038130,6,b'In addition to muscle damage, severe damage was also seen in harderian glands, especially after exposure to mepivacaine and lidocaine plus epinephrine.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'cephalosporins'\", sentence=9281, chars=[143,156], words=[22,22]), Span(\"b'hemolytic anemia'\", sentence=9281, chars=[7,22], words=[1,2]))\n",
      "Sentence(Document 1445986,1,b'Immune hemolytic anemia due to a drug-adsorption mechanism has been described primarily in patients receiving penicillins and first-generation cephalosporins.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'doxorubicin'\", sentence=10309, chars=[141,151], words=[16,16]), Span(\"b'cardiotoxicity'\", sentence=10309, chars=[8,21], words=[1,1]))\n",
      "Sentence(Document 11230490,0,b'Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.\\n')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'cyclophosphamide'\", sentence=10309, chars=[157,172], words=[18,18]), Span(\"b'cardiotoxicity'\", sentence=10309, chars=[8,21], words=[1,1]))\n",
      "Sentence(Document 11230490,0,b'Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.\\n')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'methadone'\", sentence=9778, chars=[306,314], words=[53,53]), Span(\"b'TdP'\", sentence=9778, chars=[177,179], words=[28,28]))\n",
      "Sentence(Document 17344330,3,b'As heroin addicts sometimes faint while using illicit drugs, doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of TdP in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of methadone.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'doxorubicin'\", sentence=10311, chars=[189,199], words=[36,36]), Span(\"b'MBC'\", sentence=10311, chars=[61,63], words=[11,11]))\n",
      "Sentence(Document 11230490,2,b'PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'ketorolac'\", sentence=7338, chars=[244,252], words=[48,48]), Span(\"b'pain'\", sentence=7338, chars=[88,91], words=[21,21]))\n",
      "Sentence(Document 11027904,3,b'By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'hepatitis B surface antigen'\", sentence=9301, chars=[215,241], words=[40,43]), Span(\"b'Hepatitis B'\", sentence=9301, chars=[0,10], words=[0,1]))\n",
      "Sentence(Document 343678,2,b'Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'HBsAG)-positive'\", sentence=9301, chars=[244,258], words=[45,45]), Span(\"b'Hepatitis B'\", sentence=9301, chars=[0,10], words=[0,1]))\n",
      "Sentence(Document 343678,2,b'Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'doxorubicin'\", sentence=10288, chars=[292,302], words=[43,43]), Span(\"b'myelosuppression'\", sentence=10288, chars=[47,62], words=[7,7]))\n",
      "Sentence(Document 15897593,7,b'RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'warfarin'\", sentence=7034, chars=[151,158], words=[26,26]), Span(\"b'haemorrhage'\", sentence=7034, chars=[35,45], words=[7,7]))\n",
      "Sentence(Document 19058474,1,b'We report a case of fatal internal haemorrhage in an elderly man who consumed only cranberry juice for two weeks while maintaining his usual dosage of warfarin.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'Ca(2+)](i'\", sentence=8552, chars=[251,259], words=[39,39]), Span(\"b'ventricular tachycardia'\", sentence=8552, chars=[114,136], words=[17,18]))\n",
      "Sentence(Document 19721134,3,b'The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'aconitine'\", sentence=8552, chars=[282,290], words=[44,44]), Span(\"b'fibrillation'\", sentence=8552, chars=[142,153], words=[20,20]))\n",
      "Sentence(Document 19721134,3,b'The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'ouabain'\", sentence=8552, chars=[295,301], words=[46,46]), Span(\"b'ventricular tachycardia'\", sentence=8552, chars=[114,136], words=[17,18]))\n",
      "Sentence(Document 19721134,3,b'The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'ouabain'\", sentence=8552, chars=[295,301], words=[46,46]), Span(\"b'fibrillation'\", sentence=8552, chars=[142,153], words=[20,20]))\n",
      "Sentence(Document 19721134,3,b'The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.')\n",
      "-----\n",
      "---------- LF_weak_assertions 0.0184782608696 ----------\n",
      "--------------------------------------------------\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'NSAID'\", sentence=8677, chars=[156,160], words=[29,29]), Span(\"b'urticaria'\", sentence=8677, chars=[114,122], words=[19,19]))\n",
      "Sentence(Document 11694026,9,b'However, the risk of reaction to these alternative study drugs is statistically increased by a history of chronic urticaria and, above all, by a history of NSAID-induced angioedema.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'steroid'\", sentence=10488, chars=[182,188], words=[32,32]), Span(\"b'chest pain'\", sentence=10488, chars=[92,101], words=[14,15]))\n",
      "Sentence(Document 19203554,5,b'Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'dobutamine'\", sentence=8846, chars=[107,116], words=[19,19]), Span(\"b'myocardial ischemia'\", sentence=8846, chars=[51,69], words=[10,11]))\n",
      "Sentence(Document 11078231,3,b'The aim of the present study is to examine whether myocardial ischemia due to coronary spasm is induced by dobutamine.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'levodopa'\", sentence=10840, chars=[122,129], words=[20,20]), Span(\"b'bradykinesia'\", sentence=10840, chars=[30,41], words=[3,3]))\n",
      "Sentence(Document 15096016,6,b'Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving levodopa-induced dyskinesias.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'levodopa'\", sentence=10840, chars=[122,129], words=[20,20]), Span(\"b'rigidity'\", sentence=10840, chars=[47,54], words=[5,5]))\n",
      "Sentence(Document 15096016,6,b'Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving levodopa-induced dyskinesias.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'lithium'\", sentence=10660, chars=[99,105], words=[14,14]), Span(\"b'thyroid illness'\", sentence=10660, chars=[22,36], words=[3,4]))\n",
      "Sentence(Document 10354657,14,b'CONCLUSIONS: Familial thyroid illness is a risk factor for hypothyroidism and hypercalcemia during lithium therapy.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'lithium'\", sentence=10660, chars=[99,105], words=[14,14]), Span(\"b'hypercalcemia'\", sentence=10660, chars=[78,90], words=[12,12]))\n",
      "Sentence(Document 10354657,14,b'CONCLUSIONS: Familial thyroid illness is a risk factor for hypothyroidism and hypercalcemia during lithium therapy.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'hepatitis B surface antigen'\", sentence=9301, chars=[215,241], words=[40,43]), Span(\"b'Hepatitis B'\", sentence=9301, chars=[0,10], words=[0,1]))\n",
      "Sentence(Document 343678,2,b'Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'hepatitis B surface antigen'\", sentence=9301, chars=[215,241], words=[40,43]), Span(\"b'type B hepatitis'\", sentence=9301, chars=[167,182], words=[31,33]))\n",
      "Sentence(Document 343678,2,b'Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'HBsAG)-positive'\", sentence=9301, chars=[244,258], words=[45,45]), Span(\"b'Hepatitis B'\", sentence=9301, chars=[0,10], words=[0,1]))\n",
      "Sentence(Document 343678,2,b'Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'HBsAG)-positive'\", sentence=9301, chars=[244,258], words=[45,45]), Span(\"b'type B hepatitis'\", sentence=9301, chars=[167,182], words=[31,33]))\n",
      "Sentence(Document 343678,2,b'Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'imipenem'\", sentence=10741, chars=[22,29], words=[3,3]), Span(\"b'Seizure'\", sentence=10741, chars=[0,6], words=[0,0]))\n",
      "Sentence(Document 2343592,0,b'Seizure activity with imipenem therapy: incidence and risk factors.\\n')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'malondialdehyde'\", sentence=10951, chars=[113,127], words=[19,19]), Span(\"b'ischemia'\", sentence=10951, chars=[73,80], words=[12,12]))\n",
      "Sentence(Document 7710775,8,b'nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'trihexyphenidyl'\", sentence=10084, chars=[122,136], words=[19,19]), Span(\"b'confusion'\", sentence=10084, chars=[174,182], words=[25,25]))\n",
      "Sentence(Document 18239197,1,b'OBJECTIVES: The objectives of this study were to examine the relationship between APOE epsilon4 and subjective effects of trihexyphenidyl on measures reflecting sedation and confusion and to investigate the relationship between trihexyphenidyl-induced subjective effects and objective memory performance.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'trihexyphenidyl'\", sentence=10084, chars=[228,242], words=[32,32]), Span(\"b'confusion'\", sentence=10084, chars=[174,182], words=[25,25]))\n",
      "Sentence(Document 18239197,1,b'OBJECTIVES: The objectives of this study were to examine the relationship between APOE epsilon4 and subjective effects of trihexyphenidyl on measures reflecting sedation and confusion and to investigate the relationship between trihexyphenidyl-induced subjective effects and objective memory performance.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'D-Penicillamine'\", sentence=9679, chars=[0,14], words=[0,2]), Span(\"b'renal insufficiency'\", sentence=9679, chars=[125,143], words=[20,21]))\n",
      "Sentence(Document 2334179,8,b'D-Penicillamine caused nephrotic syndrome in 1 patient and milder reversible proteinuria in 3 other patients; none developed renal insufficiency.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'doxorubicin'\", sentence=6534, chars=[174,184], words=[28,28]), Span(\"b'cardiotoxicity'\", sentence=6534, chars=[144,157], words=[23,23]))\n",
      "Sentence(Document 9848575,1,b'This study was designed to investigate the chronic cardiotoxic potential of SM-5887 and a possible deteriorating effect of SM-5887 on low-grade cardiotoxicity pre-induced by doxorubicin in beagle dogs.')\n",
      "-----\n",
      "---------- LF_c_treat_d_wide 0.0141304347826 ----------\n",
      "--------------------------------------------------\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'dexamethasone'\", sentence=10243, chars=[119,131], words=[17,17]), Span(\"b'multiple myeloma'\", sentence=10243, chars=[231,246], words=[31,32]))\n",
      "Sentence(Document 19274460,1,b'A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM).')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'angiotensin II'\", sentence=10435, chars=[17,30], words=[4,5]), Span(\"b'hypertension'\", sentence=10435, chars=[74,85], words=[12,12]))\n",
      "Sentence(Document 8841157,0,b'Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.\\n')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'angiotensin II'\", sentence=10436, chars=[61,74], words=[10,11]), Span(\"b'hypertension'\", sentence=10436, chars=[210,221], words=[36,36]))\n",
      "Sentence(Document 8841157,1,b'OBJECTIVE: To compare the antihypertensive efficacy of a new angiotensin II antagonist, valsartan, with a reference therapy, amlodipine. METHODS: One hundred sixty-eight adult outpatients with mild to moderate hypertension were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'dexamethasone'\", sentence=10250, chars=[92,104], words=[16,16]), Span(\"b'MM'\", sentence=10250, chars=[176,177], words=[27,27]))\n",
      "Sentence(Document 19274460,8,b'The results suggest that bortezomib in combination with cyclophosphamide at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'epsilon-aminocaproic acid'\", sentence=7169, chars=[46,70], words=[9,12]), Span(\"b'subarachnoid haemorrhage'\", sentence=7169, chars=[119,142], words=[25,26]))\n",
      "Sentence(Document 6674249,2,b'A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'epsilon-aminocaproic acid'\", sentence=7169, chars=[46,70], words=[9,12]), Span(\"b'SAH'\", sentence=7169, chars=[145,147], words=[28,28]))\n",
      "Sentence(Document 6674249,2,b'A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'EACA'\", sentence=7169, chars=[73,76], words=[14,14]), Span(\"b'subarachnoid haemorrhage'\", sentence=7169, chars=[119,142], words=[25,26]))\n",
      "Sentence(Document 6674249,2,b'A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'EACA'\", sentence=7169, chars=[73,76], words=[14,14]), Span(\"b'SAH'\", sentence=7169, chars=[145,147], words=[28,28]))\n",
      "Sentence(Document 6674249,2,b'A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'heparin'\", sentence=10215, chars=[53,59], words=[8,8]), Span(\"b'pelvic thrombophlebitis'\", sentence=10215, chars=[83,105], words=[12,13]))\n",
      "Sentence(Document 1255900,4,b'The disease occurred subsequent to the initiation of heparin therapy for suspected pelvic thrombophlebitis and cleared rapidly subsequent to its discontinuation.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'Calcitriol'\", sentence=8396, chars=[12,21], words=[2,2]), Span(\"b'renal failure'\", sentence=8396, chars=[101,113], words=[16,17]))\n",
      "Sentence(Document 10027919,1,b'BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'Myocet'\", sentence=10319, chars=[12,17], words=[2,2]), Span(\"b'cardiotoxicity'\", sentence=10319, chars=[91,104], words=[12,12]))\n",
      "Sentence(Document 11230490,10,b'CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'doxorubicin'\", sentence=10310, chars=[187,197], words=[29,29]), Span(\"b'MBC'\", sentence=10310, chars=[313,315], words=[46,46]))\n",
      "Sentence(Document 11230490,1,b'PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'lithium'\", sentence=10648, chars=[53,59], words=[9,9]), Span(\"b'thyroid disease'\", sentence=10648, chars=[160,174], words=[32,33]))\n",
      "Sentence(Document 10354657,2,b'These were evaluated with respect to the duration of lithium therapy, age, sex, and family history (whether or not the patient had a first-degree relative with thyroid disease).')\n",
      "-----\n",
      "---------- LF_uncertain 0.0119565217391 ----------\n",
      "--------------------------------------------------\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'dexamethasone'\", sentence=10243, chars=[119,131], words=[17,17]), Span(\"b'multiple myeloma'\", sentence=10243, chars=[231,246], words=[31,32]))\n",
      "Sentence(Document 19274460,1,b'A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM).')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'dexamethasone'\", sentence=10250, chars=[92,104], words=[16,16]), Span(\"b'MM'\", sentence=10250, chars=[176,177], words=[27,27]))\n",
      "Sentence(Document 19274460,8,b'The results suggest that bortezomib in combination with cyclophosphamide at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'naloxone'\", sentence=6969, chars=[47,54], words=[7,7]), Span(\"b'hypotension'\", sentence=6969, chars=[75,85], words=[12,12]))\n",
      "Sentence(Document 1928887,5,b'Our experience demonstrates a possible role of naloxone in the reversal of hypotension resulting from captopril.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'cyclophosphamide'\", sentence=10311, chars=[241,256], words=[50,50]), Span(\"b'toxicity'\", sentence=10311, chars=[319,326], words=[63,63]))\n",
      "Sentence(Document 11230490,2,b'PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'C'\", sentence=10311, chars=[259,259], words=[52,52]), Span(\"b'toxicity'\", sentence=10311, chars=[319,326], words=[63,63]))\n",
      "Sentence(Document 11230490,2,b'PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'bortezomib'\", sentence=10242, chars=[84,93], words=[12,12]), Span(\"b'myeloma'\", sentence=10242, chars=[166,172], words=[23,23]))\n",
      "Sentence(Document 19274460,0,b'DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.\\n')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'dexamethasone'\", sentence=10242, chars=[95,107], words=[14,14]), Span(\"b'myeloma'\", sentence=10242, chars=[166,172], words=[23,23]))\n",
      "Sentence(Document 19274460,0,b'DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.\\n')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'cisapride'\", sentence=7470, chars=[75,83], words=[14,14]), Span(\"b'gastroesophageal reflux disorder'\", sentence=7470, chars=[89,120], words=[16,18]))\n",
      "Sentence(Document 9545159,3,b'A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'doxorubicin'\", sentence=10310, chars=[187,197], words=[29,29]), Span(\"b'cardiotoxicity'\", sentence=10310, chars=[199,212], words=[30,30]))\n",
      "Sentence(Document 11230490,1,b'PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'doxorubicin'\", sentence=10310, chars=[187,197], words=[29,29]), Span(\"b'MBC'\", sentence=10310, chars=[313,315], words=[46,46]))\n",
      "Sentence(Document 11230490,1,b'PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'cyclophosphamide'\", sentence=10310, chars=[148,163], words=[26,26]), Span(\"b'cardiotoxicity'\", sentence=10310, chars=[199,212], words=[30,30]))\n",
      "Sentence(Document 11230490,1,b'PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).')\n",
      "-----\n",
      "---------- LF_ctd_therapy_treat 0.00978260869565 ----------\n",
      "--------------------------------------------------\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'dexamethasone'\", sentence=10243, chars=[119,131], words=[17,17]), Span(\"b'multiple myeloma'\", sentence=10243, chars=[231,246], words=[31,32]))\n",
      "Sentence(Document 19274460,1,b'A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM).')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'dexamethasone'\", sentence=10250, chars=[92,104], words=[16,16]), Span(\"b'MM'\", sentence=10250, chars=[176,177], words=[27,27]))\n",
      "Sentence(Document 19274460,8,b'The results suggest that bortezomib in combination with cyclophosphamide at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'epsilon-aminocaproic acid'\", sentence=7169, chars=[46,70], words=[9,12]), Span(\"b'subarachnoid haemorrhage'\", sentence=7169, chars=[119,142], words=[25,26]))\n",
      "Sentence(Document 6674249,2,b'A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'epsilon-aminocaproic acid'\", sentence=7169, chars=[46,70], words=[9,12]), Span(\"b'SAH'\", sentence=7169, chars=[145,147], words=[28,28]))\n",
      "Sentence(Document 6674249,2,b'A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'EACA'\", sentence=7169, chars=[73,76], words=[14,14]), Span(\"b'subarachnoid haemorrhage'\", sentence=7169, chars=[119,142], words=[25,26]))\n",
      "Sentence(Document 6674249,2,b'A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'EACA'\", sentence=7169, chars=[73,76], words=[14,14]), Span(\"b'SAH'\", sentence=7169, chars=[145,147], words=[28,28]))\n",
      "Sentence(Document 6674249,2,b'A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'heparin'\", sentence=10215, chars=[53,59], words=[8,8]), Span(\"b'pelvic thrombophlebitis'\", sentence=10215, chars=[83,105], words=[12,13]))\n",
      "Sentence(Document 1255900,4,b'The disease occurred subsequent to the initiation of heparin therapy for suspected pelvic thrombophlebitis and cleared rapidly subsequent to its discontinuation.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'Calcitriol'\", sentence=8396, chars=[12,21], words=[2,2]), Span(\"b'renal failure'\", sentence=8396, chars=[101,113], words=[16,17]))\n",
      "Sentence(Document 10027919,1,b'BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'doxorubicin'\", sentence=10310, chars=[187,197], words=[29,29]), Span(\"b'MBC'\", sentence=10310, chars=[313,315], words=[46,46]))\n",
      "Sentence(Document 11230490,1,b'PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).')\n",
      "-----\n",
      "---------- LF_level 0.00869565217391 ----------\n",
      "--------------------------------------------------\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'creatine'\", sentence=7586, chars=[37,44], words=[5,5]), Span(\"b'systemic lupus erythematosus'\", sentence=7586, chars=[63,90], words=[9,11]))\n",
      "Sentence(Document 12739036,0,b'Differential diagnosis of high serum creatine kinase levels in systemic lupus erythematosus.\\n')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'lithium'\", sentence=6272, chars=[107,113], words=[18,18]), Span(\"b'tricuspid regurgitation'\", sentence=6272, chars=[23,45], words=[4,5]))\n",
      "Sentence(Document 6794356,1,b'A newborn with massive tricuspid regurgitation, atrial flutter, congestive heart failure, and a high serum lithium level is described.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'lithium'\", sentence=6272, chars=[107,113], words=[18,18]), Span(\"b'atrial flutter'\", sentence=6272, chars=[48,61], words=[7,8]))\n",
      "Sentence(Document 6794356,1,b'A newborn with massive tricuspid regurgitation, atrial flutter, congestive heart failure, and a high serum lithium level is described.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'lithium'\", sentence=6272, chars=[107,113], words=[18,18]), Span(\"b'congestive heart failure'\", sentence=6272, chars=[64,87], words=[10,12]))\n",
      "Sentence(Document 6794356,1,b'A newborn with massive tricuspid regurgitation, atrial flutter, congestive heart failure, and a high serum lithium level is described.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'lactate'\", sentence=8519, chars=[80,86], words=[13,13]), Span(\"b'lactic acidosis'\", sentence=8519, chars=[11,25], words=[1,2]))\n",
      "Sentence(Document 3703509,4,b'Nonketotic lactic acidosis was present in one and ketosis without a known serum lactate level was present in the other.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'lactate'\", sentence=8519, chars=[80,86], words=[13,13]), Span(\"b'ketosis'\", sentence=8519, chars=[50,56], words=[8,8]))\n",
      "Sentence(Document 3703509,4,b'Nonketotic lactic acidosis was present in one and ketosis without a known serum lactate level was present in the other.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'Calcitriol'\", sentence=8396, chars=[12,21], words=[2,2]), Span(\"b'renal failure'\", sentence=8396, chars=[101,113], words=[16,17]))\n",
      "Sentence(Document 10027919,1,b'BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'OCT'\", sentence=8398, chars=[54,56], words=[9,9]), Span(\"b'impaired renal function'\", sentence=8398, chars=[119,141], words=[22,24]))\n",
      "Sentence(Document 10027919,3,b'This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or impaired renal function.')\n",
      "-----\n",
      "---------- LF_d_treat_c 0.00760869565217 ----------\n",
      "--------------------------------------------------\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'Li'\", sentence=6777, chars=[117,118], words=[24,24]), Span(\"b'akathisia'\", sentence=6777, chars=[17,25], words=[3,3]))\n",
      "Sentence(Document 17042884,10,b'The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'corticosteroids'\", sentence=9443, chars=[107,121], words=[17,17]), Span(\"b'myopathy'\", sentence=9443, chars=[46,53], words=[7,7]))\n",
      "Sentence(Document 8665051,1,b'Occasional case reports have shown that acute myopathy may occur in patients treated with massive doses of corticosteroids.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'phenytoin'\", sentence=10744, chars=[55,63], words=[8,8]), Span(\"b'seizures'\", sentence=10744, chars=[4,11], words=[1,1]))\n",
      "Sentence(Document 2343592,3,b'All seizures were controlled with therapeutic doses of phenytoin.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'penicillin'\", sentence=9950, chars=[134,143], words=[28,28]), Span(\"b'acute renal failure'\", sentence=9950, chars=[66,84], words=[12,14]))\n",
      "Sentence(Document 4069770,1,b'The clinical and autopsy findings in a premature baby who died of acute renal failure after therapy with gentamicin (5 mg/kg/day) and penicillin are presented.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'cyclophosphamide'\", sentence=7588, chars=[155,170], words=[25,25]), Span(\"b'renal involvement'\", sentence=7588, chars=[80,96], words=[15,16]))\n",
      "Sentence(Document 12739036,2,b'Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'naloxone'\", sentence=6968, chars=[96,103], words=[17,17]), Span(\"b'hypotension'\", sentence=6968, chars=[71,81], words=[14,14]))\n",
      "Sentence(Document 1928887,4,b'To our knowledge, this is the first reported case of captopril-induced hypotension treated with naloxone.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'D-penicillamine'\", sentence=9674, chars=[95,109], words=[15,17]), Span(\"b'localized scleroderma'\", sentence=9674, chars=[51,71], words=[9,10]))\n",
      "Sentence(Document 2334179,3,b'Case reports of 11 patients with severe, extensive localized scleroderma who were treated with D-penicillamine are summarized in this article.')\n",
      "-----\n",
      "---------- LF_ctd_unspecified_treat 0.00652173913043 ----------\n",
      "--------------------------------------------------\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'dexamethasone'\", sentence=10243, chars=[119,131], words=[17,17]), Span(\"b'multiple myeloma'\", sentence=10243, chars=[231,246], words=[31,32]))\n",
      "Sentence(Document 19274460,1,b'A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM).')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'angiotensin II'\", sentence=10435, chars=[17,30], words=[4,5]), Span(\"b'hypertension'\", sentence=10435, chars=[74,85], words=[12,12]))\n",
      "Sentence(Document 8841157,0,b'Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.\\n')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'angiotensin II'\", sentence=10436, chars=[61,74], words=[10,11]), Span(\"b'hypertension'\", sentence=10436, chars=[210,221], words=[36,36]))\n",
      "Sentence(Document 8841157,1,b'OBJECTIVE: To compare the antihypertensive efficacy of a new angiotensin II antagonist, valsartan, with a reference therapy, amlodipine. METHODS: One hundred sixty-eight adult outpatients with mild to moderate hypertension were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'dexamethasone'\", sentence=10250, chars=[92,104], words=[16,16]), Span(\"b'MM'\", sentence=10250, chars=[176,177], words=[27,27]))\n",
      "Sentence(Document 19274460,8,b'The results suggest that bortezomib in combination with cyclophosphamide at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'Calcitriol'\", sentence=8396, chars=[12,21], words=[2,2]), Span(\"b'renal failure'\", sentence=8396, chars=[101,113], words=[16,17]))\n",
      "Sentence(Document 10027919,1,b'BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'doxorubicin'\", sentence=10310, chars=[187,197], words=[29,29]), Span(\"b'MBC'\", sentence=10310, chars=[313,315], words=[46,46]))\n",
      "Sentence(Document 11230490,1,b'PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).')\n",
      "-----\n",
      "---------- LF_c_treat_d 0.0054347826087 ----------\n",
      "--------------------------------------------------\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'angiotensin II'\", sentence=10435, chars=[17,30], words=[4,5]), Span(\"b'hypertension'\", sentence=10435, chars=[74,85], words=[12,12]))\n",
      "Sentence(Document 8841157,0,b'Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.\\n')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'dexamethasone'\", sentence=10250, chars=[92,104], words=[16,16]), Span(\"b'MM'\", sentence=10250, chars=[176,177], words=[27,27]))\n",
      "Sentence(Document 19274460,8,b'The results suggest that bortezomib in combination with cyclophosphamide at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'epsilon-aminocaproic acid'\", sentence=7169, chars=[46,70], words=[9,12]), Span(\"b'subarachnoid haemorrhage'\", sentence=7169, chars=[119,142], words=[25,26]))\n",
      "Sentence(Document 6674249,2,b'A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'EACA'\", sentence=7169, chars=[73,76], words=[14,14]), Span(\"b'subarachnoid haemorrhage'\", sentence=7169, chars=[119,142], words=[25,26]))\n",
      "Sentence(Document 6674249,2,b'A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'heparin'\", sentence=10215, chars=[53,59], words=[8,8]), Span(\"b'pelvic thrombophlebitis'\", sentence=10215, chars=[83,105], words=[12,13]))\n",
      "Sentence(Document 1255900,4,b'The disease occurred subsequent to the initiation of heparin therapy for suspected pelvic thrombophlebitis and cleared rapidly subsequent to its discontinuation.')\n",
      "-----\n",
      "---------- LF_closer_dis 0.00434782608696 ----------\n",
      "--------------------------------------------------\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'doxorubicin'\", sentence=10310, chars=[187,197], words=[29,29]), Span(\"b'MBC'\", sentence=10310, chars=[313,315], words=[46,46]))\n",
      "Sentence(Document 11230490,1,b'PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'daunorubicin'\", sentence=10288, chars=[85,96], words=[12,12]), Span(\"b'myelosuppression'\", sentence=10288, chars=[226,241], words=[32,32]))\n",
      "Sentence(Document 15897593,7,b'RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'daunorubicin'\", sentence=10288, chars=[85,96], words=[12,12]), Span(\"b'cytotoxicity'\", sentence=10288, chars=[274,285], words=[41,41]))\n",
      "Sentence(Document 15897593,7,b'RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'doxorubicin'\", sentence=10288, chars=[292,302], words=[43,43]), Span(\"b'myelosuppression'\", sentence=10288, chars=[47,62], words=[7,7]))\n",
      "Sentence(Document 15897593,7,b'RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.')\n",
      "-----\n",
      "---------- LF_improve_before_disease 0.00434782608696 ----------\n",
      "--------------------------------------------------\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'steroid'\", sentence=10488, chars=[182,188], words=[32,32]), Span(\"b'chest pain'\", sentence=10488, chars=[92,101], words=[14,15]))\n",
      "Sentence(Document 19203554,5,b'Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'levodopa'\", sentence=10840, chars=[122,129], words=[20,20]), Span(\"b'bradykinesia'\", sentence=10840, chars=[30,41], words=[3,3]))\n",
      "Sentence(Document 15096016,6,b'Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving levodopa-induced dyskinesias.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'levodopa'\", sentence=10840, chars=[122,129], words=[20,20]), Span(\"b'rigidity'\", sentence=10840, chars=[47,54], words=[5,5]))\n",
      "Sentence(Document 15096016,6,b'Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving levodopa-induced dyskinesias.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'cyclophosphamide'\", sentence=10319, chars=[204,219], words=[28,28]), Span(\"b'cardiotoxicity'\", sentence=10319, chars=[91,104], words=[12,12]))\n",
      "Sentence(Document 11230490,10,b'CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.')\n",
      "-----\n",
      "---------- LF_induced_other 0.00434782608696 ----------\n",
      "--------------------------------------------------\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'anthracycline'\", sentence=6533, chars=[37,49], words=[6,6]), Span(\"b'cardiomyopathy'\", sentence=6533, chars=[112,125], words=[18,18]))\n",
      "Sentence(Document 9848575,0,b'Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs.\\n')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'paracetamol'\", sentence=8670, chars=[77,87], words=[11,11]), Span(\"b'urticaria'\", sentence=8670, chars=[183,191], words=[30,30]))\n",
      "Sentence(Document 11694026,2,b'In this study we investigated tolerability and reliability of nimesulide and paracetamol in a very large number of patients with an exclusive well-documented history of NSAID-induced urticaria/angioedema.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'paracetamol'\", sentence=8668, chars=[31,41], words=[4,4]), Span(\"b'urticaria'\", sentence=8668, chars=[74,82], words=[11,11]))\n",
      "Sentence(Document 11694026,0,b'Tolerability of nimesulide and paracetamol in patients with NSAID-induced urticaria/angioedema.\\n')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'paracetamol'\", sentence=8672, chars=[72,82], words=[12,12]), Span(\"b'urticaria'\", sentence=8672, chars=[144,152], words=[25,25]))\n",
      "Sentence(Document 11694026,4,b'A single-placebo-controlled oral challenge procedure with nimesulide or paracetamol was applied to 829 patients with a history of NSAID-induced urticaria/angioedema.')\n",
      "-----\n",
      "---------- LF_treat_d 0.00326086956522 ----------\n",
      "--------------------------------------------------\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'steroid'\", sentence=10488, chars=[182,188], words=[32,32]), Span(\"b'chest pain'\", sentence=10488, chars=[92,101], words=[14,15]))\n",
      "Sentence(Document 19203554,5,b'Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'hepatitis B surface antigen'\", sentence=9301, chars=[215,241], words=[40,43]), Span(\"b'type B hepatitis'\", sentence=9301, chars=[167,182], words=[31,33]))\n",
      "Sentence(Document 343678,2,b'Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'HBsAG)-positive'\", sentence=9301, chars=[244,258], words=[45,45]), Span(\"b'type B hepatitis'\", sentence=9301, chars=[167,182], words=[31,33]))\n",
      "Sentence(Document 343678,2,b'Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.')\n",
      "-----\n",
      "---------- LF_d_induced_by_c 0.00217391304348 ----------\n",
      "--------------------------------------------------\n",
      "GT: 1 LF: 1 Gen: -1\n",
      "ChemicalDisease(Span(\"b'glyceryl trinitrate'\", sentence=8835, chars=[107,125], words=[19,20]), Span(\"b'headache'\", sentence=8835, chars=[74,81], words=[13,13]))\n",
      "Sentence(Document 11284996,2,b'In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.')\n",
      "-----\n",
      "GT: 1 LF: 1 Gen: -1\n",
      "ChemicalDisease(Span(\"b'GTN'\", sentence=8835, chars=[128,130], words=[22,22]), Span(\"b'headache'\", sentence=8835, chars=[74,81], words=[13,13]))\n",
      "Sentence(Document 11284996,2,b'In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.')\n",
      "-----\n",
      "---------- LF_neg_d 0.00217391304348 ----------\n",
      "--------------------------------------------------\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'acetylcholine'\", sentence=8849, chars=[57,69], words=[8,8]), Span(\"b'coronary artery stenosis'\", sentence=8849, chars=[85,108], words=[13,15]))\n",
      "Sentence(Document 11078231,6,b'Coronary spasm was induced by intracoronary injection of acetylcholine, and no fixed coronary artery stenosis was documented on angiograms in all patients.')\n",
      "-----\n",
      "GT: -1 LF: -1 Gen: 1\n",
      "ChemicalDisease(Span(\"b'D-Penicillamine'\", sentence=9679, chars=[0,14], words=[0,2]), Span(\"b'renal insufficiency'\", sentence=9679, chars=[125,143], words=[20,21]))\n",
      "Sentence(Document 2334179,8,b'D-Penicillamine caused nephrotic syndrome in 1 patient and milder reversible proteinuria in 3 other patients; none developed renal insufficiency.')\n",
      "-----\n",
      "---------- LF_c_cause_d 0.00108695652174 ----------\n",
      "--------------------------------------------------\n",
      "GT: 1 LF: 1 Gen: -1\n",
      "ChemicalDisease(Span(\"b'Lithium'\", sentence=6778, chars=[0,6], words=[0,0]), Span(\"b'tremor'\", sentence=6778, chars=[75,80], words=[14,14]))\n",
      "Sentence(Document 17042884,11,b'Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.')\n",
      "-----\n",
      "---------- LF_c_d 0.0 ----------\n",
      "--------------------------------------------------\n",
      "---------- LF_c_induced_d 0.0 ----------\n",
      "--------------------------------------------------\n",
      "---------- LF_ctd_marker_c_d 0.0 ----------\n",
      "--------------------------------------------------\n",
      "---------- LF_ctd_marker_induce 0.0 ----------\n",
      "--------------------------------------------------\n",
      "---------- LF_ctd_unspecified_induce 0.0 ----------\n",
      "--------------------------------------------------\n",
      "---------- LF_d_following_c 0.0 ----------\n",
      "--------------------------------------------------\n",
      "---------- LF_d_induced_by_c_tight 0.0 ----------\n",
      "--------------------------------------------------\n",
      "---------- LF_develop_d_following_c 0.0 ----------\n",
      "--------------------------------------------------\n",
      "---------- LF_in_patient_with 0.0 ----------\n",
      "--------------------------------------------------\n",
      "---------- LF_induce 0.0 ----------\n",
      "--------------------------------------------------\n",
      "---------- LF_induce_name 0.0 ----------\n",
      "--------------------------------------------------\n",
      "---------- LF_measure 0.0 ----------\n",
      "--------------------------------------------------\n",
      "---------- LF_risk_d 0.0 ----------\n",
      "--------------------------------------------------\n"
     ]
    }
   ],
   "source": [
    "import numpy as np\n",
    "\n",
    "def better_lf_scores(L, gen_labels, gt, L_fns):\n",
    "    results = {}\n",
    "    for lf_label, lf in zip(L, L_fns):\n",
    "        # LF correct but generative model wrong\n",
    "        lf_over_gen = np.logical_and(gen_labels != gt, lf_label == gt)\n",
    "        num_lf_over_gen = np.sum(lf_over_gen)\n",
    "\n",
    "        results[lf.__name__]= {\n",
    "            'idx': np.where(lf_over_gen)[0],\n",
    "            'lf_label': lf_label,\n",
    "            'score': num_lf_over_gen/len(gen_labels)\n",
    "        }\n",
    "\n",
    "    # pring overall scores\n",
    "    sorted_dict = sorted(results.items(), key=lambda kv: kv[1]['score'], reverse=True)\n",
    "    for k,v in sorted_dict:\n",
    "        print ('-'*10, k, v['score'], '-'*10)\n",
    "        print ('-'*50)\n",
    "        for idx in v['idx']:\n",
    "            c = dev_cands[idx]\n",
    "            sent = c.get_parent()\n",
    "            print ('GT:', gt[idx], 'LF:', v['lf_label'][idx], 'Gen:', gen_labels[idx])\n",
    "            print (c)\n",
    "            print (sent)\n",
    "            print ('-'*5)\n",
    "\n",
    "# convert marginals to hard labels\n",
    "dev_rounded_labels = labels = 2 * (dev_marginals > 0.5) - 1\n",
    "better_lf_scores(L_dev.toarray().T, dev_rounded_labels, np.squeeze(L_gold_dev.toarray()), LFs)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "anaconda-cloud": {},
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.6.5"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 1
}
